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Proteins are diverse polymers of covalently linked amino acids. They play a role 
in almost every biological process that occurs within an organism. Twenty different 
amino acids are genetically encoded by mammalian cells to build proteins. The sequence 
of these amino acids determines the protein’s final shape, structure, and function. Modern 
molecular cloning techniques allow for the genetic encoding and expression of mutant 
proteins that have one or more amino acids replaced with one of the others. The roles of 
individual amino acids in a protein can therefore be studied. Proteins with novel functions 
have also been designed or evolved using this technology. However, the genetic code is 
limited to the twenty natural amino acids. 
Nonnatural amino acids have unique side groups that not found on any of the 
twenty natural amino acids. They can be site-specifically incorporated using a mutant 
orthogonal suppressor tRNA/aminoacyl-tRNA synthetase (aaRS) pair. Each pair only 
allows for one type of nonnatural amino acid to be genetically encoded. This technology 
has resulted in the incorporation of over fifty different types of nonnatural amino acids 
into proteins in prokaryotic and eukaryotic cells. Unfortunately, most of these pairs are 
not orthogonal outside of prokaryotic systems and only a few have been developed for 
mammalian cells. To create more mammalian pairs a nonnatural aaRS has to be evolved 
and screened in a cumbersome process. In this dissertation an approach is outlined that 
 vii
can be used to change the orthogonality of existing nonnatural suppressor tRNA/aaRS 
pairs. As a result of the orthogonality change many previously unavailable pairs can be 
shuttled into mammalian cells. The ability to genetically encode a 21st amino acid is a 
powerful tool in the study and engineering of proteins. 
 viii
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Nonnatural Amino Acid Containing Proteins 
 
1.1 INTRODUCTION 
All living organisms use amino acids as the basic building blocks to assemble 
proteins. These proteins are defined by a unique sequence of covalently linked amino 
acid residues which determines its final structure and function. Discovery of the genetic 
code has revealed the mechanism by which DNA is used to store a protein’s specific 
sequence. Twenty natural amino acids that contain different side chains can be 
genetically encoded this way. Advancements in molecular cloning techniques have 
allowed us to express any amino acid sequence by encoding the information within a 
DNA template. In the past few decades, progress has also been made in the design and 
expression of proteins containing nonnatural amino acids [1]. These are usually analogs 
of their natural counterparts but contain atypical side chains (Figure 1.1) with unique 
chemical, fluorescent, or physical attributes. Nonnatural amino acid can be used to 




Figure 1.1: Structure of tyrosine and the nonnatural amino acids p-acetyl-L-
phenylalanine and 3,4-dihydroxy-L-phenylalanine (L-DOPA). Although 
they are have a similar backbone, nonnatural amino acids have atypical side 
chains that contain functional groups which are not found on any of the 
twenty natural amino acids.  
Nonnatural amino acids can be a powerful tool in advancing our understanding of 
proteins. Evidence suggests that cells require more diverse building blocks than the 
natural amino acids. For example, post-translational modification processes are often 
employed by cells to chemically modify one or more side chains on a protein [2]. 
Nonnatural amino acids can be used to mimic these modifications in order to study their 
purpose and effects. Protein engineering is another field that can greatly benefit from the 
use of nonnatural amino acids [3]. Roger Tsien’s group have engineered a number of 
GFP variants with novel fluorescent properties by substituting various residues in the 
GFP with one of the other twenty [4]. Side chains can be directly involved in the 
functionality of the protein and there exists a lot more diversity between the nonnatural 
amino acids. Therefore, they can allow more possible protein designs. This chapter will 
review some of the current methods of incorporating nonnatural amino acids into a 
protein and some of their applications. 
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1.2 PROTEIN STUDIES USING NONNATURAL AMINO ACIDS 
Nonnatural amino acids can be incorporated into a protein using chemical or 
biosynthetic methods. In vitro or in vivo biosynthetic techniques are usually preferred 
because chemical synthesis is costly and cannot be used to produce large proteins [5]. 
These methods involve the manipulation of the aminoacylation reaction when a tRNA is 
covalently attached (charged) to an amino acid. A nonnatural amino acid charged tRNA 
can be used to incorporate a nonnatural amino acid during protein translation. After 
mRNA is transcribed from a DNA sequence, the transcript is translated into an amino 
acid sequence by the ribosome complex. Correct base pairing between the mRNA 
(codon) and charged tRNA (anticodon) regions will result in the transfer of the attached 
amino acid to the growing peptide chain (Figure 1.2). The ribosome does not proofread 
the attached amino acid so a mischarged tRNA can result in the wrong amino acid being 
added to a protein. Two different biosynthetic approaches take advantage of this 




Figure 1.2: Aminoacyl-tRNA synthetases (aaRS) catalyze the covalent attachment of an 
amino acid to a corresponding tRNA. Biosynthetic methods techniques use 
tRNAs that have been charged with a nonnatural amino acid. Correct base 
pairing between the mRNA and tRNA (red circle) is the only requirement 
for the attached amino acid to be added to the growing peptide chain. 
(Adobe Flash CS5) 
Residue-specific incorporation uses endogenous cellular machinery to replace one 
of the twenty natural amino acids in the genetic code with a nonnatural amino acid [6]. 
This has proven useful when one wants to incorporate a nonnatural amino acid into all 
proteins within the host. This can also greatly affect the overall properties of the protein 
since several residues are usually replaced (Figure 1.3). Site-specific incorporation 
expands the genetic code through the use of mutant orthogonal suppressor 
tRNA/aminoacyl-tRNA synthetase (aaRS) pairs. Each pair corresponds to a specific 
nonnatural amino acid. Proteins composed of twenty one amino acids can therefore be 
 5
produced, and the location of the nonnatural amino acid genetically encoded. The effect 
of the nonnatural amino acid on the protein can be minimized since it is genetically 
encoded (Figure 1.3). This can allow a nonnatural amino acid incorporated protein to be 
expressed without affecting other cellular proteins [3]. In the following sections we 
review the science and methodology behind both biosynthetic approaches as well as 
highlighting some of the applications currently demonstrated by using these techniques. 
 
 
Figure 1.3: Residue specific incorporation replaces one type of amino acid (i.e. tyrosine 
shown in red) with the nonnatural amino acid. As a result, all residues 
within the protein are replaced resulting in dramatic changes in the overall 
properties of the protein. In addition, all cellular proteins will the host will 
be affected. Site-specific incorporation can be used to target the nonnatural 
amino acid to a specific location within the protein, this allows for more fine 
tuned modifications. Images were created with the PyMOL Molecular 
Graphics System (pymol.org) 
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1.2.1 Residue-specific Incorporation 
Some natural aminoacyl-tRNA synthetases (aaRS) are promiscuous in identifying 
their target amino acid [7]. These wild type aaRS can be tricked into charging their 
cognate tRNAs with a nonnatural amino acid analog if it is supplied at a high enough 
concentration. Cohen and coworkers first demonstrated this in the 1950’s when they 
quantitatively incorporated analogs such as seleno-methionine [8], nor-leucine, and para-
fluorophenylalanine [9] in place of their natural amino acids. All amino acids of a chosen 
type in the cell will have an equal chance of being replaced by the nonnatural amino acid. 
There is no genetic manipulation required since endogenous tRNA/aaRS pairs are used. 
Furthermore, nonnatural amino acids can be incorporated into any protein within a cell 
without having to know its sequence [6]. 
Numerous studies have shown the various applications of residue-specific 
incorporation. Dieterich et al. devised a bio-orthogonal noncanonical (nonnatural) amino 
acid tagging method (BONCAT) to pulse label newly synthesized proteins with the 
nonnatural amino acid azidohomoalanine [10].  Cells are first grown in normal medium 
which results in the synthesis of proteins containing the twenty natural amino acids. 
When alanine was replaced with azidohomoalanine in the growth media, all newly 
translated proteins will have an azidohomoalanine in place of an alanine. The azide 
functional group is not present on any of the natural amino acids, thus these nonnatural 
amino acid containing proteins can be selectively purified and identified. Another 
temporal labeling application was demonstrated by Tirrell and coworkers when they used 
two methionine analogs (azidohomoalanine and homopropargylglycine) to pulse-label 
proteins at two different time points in mammalian cells [11]. As with the one nonnatural 
amino acid labeling technique, cells were first grown in normal medium and then 
switched to media where methionine was replaced with azidohomoalanine followed by 
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homopropargylglycine. Fluorescent molecules can be used to label these proteins by 
covalently linking them to the unique functional groups on the nonnatural amino acids. 
Proteins synthesized when the nonnatural amino acid was present in the medium would 
contain it in place of alanine. They demonstrate the use of nonnatural amino acids as an 
easier and safer alternative to conventional methods that often use radioactive materials 
[12]. 
Another area of application for residue-specific incorporation is the production of 
proteins with modified properties [6]. Since multiple resides within a protein are usually 
replaced with the nonnatural amino acid, the folding and functional characteristics of the 
protein can be greatly affected. The melting temperature of a collagen peptide was shown 
to increase by more than 50 ºC when nonnatural amino acids were substituted in place of 
proline [13]. Shoulders et al. replaced all of the proline residues within the collagen 
motif, proline-proline-glycine, with 4-fluoroproline and 4-methylproline. The resulting 
nonnatural amino acid containing collagen peptide still formed a triple helix structure that 
was similar to natural collagen but exhibited much better thermostability. Another 
example is when Yoo and coworkers replaced all the leucine residues in green 
fluorescent protein with 5,5,5-trifluoroleucine. Then by using directed evolution, they 
were able to isolate a mutant that contained fifteen residues of 5,5,5-trifluoroleucine. 
Even though it contained several nonnatural amino acids it still had similar folding and 
fluorescence properties to that of wild type GFP [14]. Lepthien et al. created a blue 
fluorescent human annexin protein when they replaced a tryptophan residue with 4-
azatryptophan [15]. This demonstrated a very simple way to directly visualize and track 
the location of a protein without having to covalently attach a fluorescent molecule [16]. 
The ability of nonnatural amino acids to affect the characteristics of a protein’s active site 
is also an area of research. 
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 Residue-specific incorporation is limited by the fact that it relies on the low 
activity of endogenous amino-tRNA synthetases (aaRS) for natural amino acid analogs. 
The nonnatural amino acid must be supplied either in replacement or at a much higher 
concentration than the natural amino acid. Auxotrophic strains are commonly used to 
improve the incorporation efficiency by minimizing background [17].The fidelity of 
endogenous aaRS can also be reduced by mutating its active site to increase the activity 
of the synthetase for the nonnatural amino acid [18]. Although global incorporation can 
be beneficial in studies where the modification of all proteins is required, too much 
nonnatural amino acid content could very likely have a negative impact on protein 
folding and function. Proteins other than the one of interest would also have every amino 
acid of one type replaced by the nonnatural amino acid. BONCAT can be used as a tool 
to isolate newly synthesized proteins under various conditions, but the global 
modification of all cellular proteins limits the significance of such studies. 
 
1.2.2 Site-specific Incorporation 
 Site-specific incorporation can be used to add a single nonnatural amino acid 
anywhere within a protein without globally affecting the host cell’s proteins. A method 
was developed, independently, by Schultz [19] and Chamberlain [20] to genetically 
encode a nonnatural amino acid using a stop codon. All three nucleotide combinations are 
used by the cell to encode for one of the twenty natural amino acids. Only the three stop 
codons amber (TAG), ochre (TAA), and opal (TGA) do not encode an amino acid and 
instead are used to signal translation termination. However, if an aminoacylated tRNA 
with a mutation in the anticodon region can correctly base pair with the stop codon then 
protein translation will continue [21]. Any stop codon that appears in a gene could be 
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effectively ‘suppressed’ as long as the cell has a charged suppressor tRNA. So, they first 
modified a tRNA gene in its anticodon sequence (GUA to CUA) and then transcribed it 
in vitro. This ‘suppressor’ tRNA folded correctly and was chemically aminoacylated with 
a phenylalanine analog. Next, an mRNA construct was created for a gene of interest. A 
codon within the gene was changed to the amber stop codon (TAG). This would normally 
cause translation to halt, but the suppressor tRNA can base pair with the TAG sequence 
and allow translation to continue. The ribosome lacks the ability to proofread the identity 
of the amino acid on the tRNA and will transfer it as long as correct base pairing occurs 
between the tRNA anticodon and mRNA codon sequences. These components were used 
with an in vitro cell-free translation system in order to incorporate several phenylalanine 
analogs site-specifically [19]. However, the amount of protein generated by this approach 
is limited since a tRNA cannot be recharged once it has transferred the attached amino 
acid. Any protein with a known DNA sequence can be modified with a nonnatural amino 
acid using this method. 
 This technique was next expanded to in vivo experiments when an amber 
suppressor tRNA was aminoacylated with a tyrosine analog and injected into Xenopus 
oocytes [22]. An mRNA constructs containing the gene for the nicotinic acetylcholine 
receptor had a codon replaced with the amber stop codon and was also injected into the 
oocytes. As a result, they demonstrated in vivo site-specific incorporation of a nonnatural 
amino acid in response to a stop codon. But this technique was still limited by the amount 
of nonnatural amino acid containing proteins produced since there was no way to 
regenerate (recharge) the suppressor tRNA in the cells. Schultz later resolved the tRNA 
limitation and applied his approach to in vivo systems when he developed and introduced 
an orthogonal suppressor tRNA/aminoacyl-tRNA synthetase (aaRS) into cells as a 21st 
pair [23]. They identified a tyrosyl-tRNA/tyrosyl-tRNA synthetase (TyrRS) from 
 10
Methanococcus jannaschii that was orthogonal in Escherichia coli cells [24]. 
Orthogonality of this pair ensured that endogenous E. coli TyrRS would not aminoacylate 
the M. jannaschii tRNA nor would the M. jannaschii TyrRS aminoacylate any E. coli 
tyrosyl-tRNA. The gene for M. jannaschii tyrosyl-tRNA was modified in its anticodon 
sequence from GUA to CUA to allow it to base pair to the amber stop codon (TAG). The 
M. jannaschii TyrRS’s active site was then mutated to change its specificity from 
tyrosine to a nonnatural amino acid [23]. They identified five residues within the 
enzyme’s active site (Tyr32, Glu107, Asp158, Ile159, and Leu162) responsible for 
recognizing the amino acid side chain. A plasmid library of TyrRS mutants was created 
by randomly mutating all five locations. Cells transformed with the library were screened 
with a round of positive selection (Figure 1.4) to identify mutants that could recognize a 
tyrosine analog (O-methyl-L-tyrosine). Negative selection was then used to remove 
mutants that could still recognize tyrosine. Alternating rounds of positive and negative 
selection he most active and specific mutant TyrRS to be identified. To incorporate the 
nonnatural amino acid site-specifically, they mutated the third codon of a gene for 
dihydrofolate reductase to the amber stop codon. E. coli cells were transformed with a 
plasmid containing the mutated dihydrofolate reductase gene, a gene for the suppressor 
tRNA, and the nonnatural aaRS gene. When the cells were supplied with a nonnatural 
amino acid in the media, the E. coli cells were able to produce mutant dihydrofolate 
reductase proteins containing O-methyl-L-tyrosine in the third position [23].  
Each nonnatural amino acid requires a new nonnatural aaRS. Several of these 
pairs have been evolved to incorporate many nonnatural amino acids. Two pairs of 
interest are the ones for the nonnatural amino acids p-acetyl-L-phenylalanine [25] and 
3,4-dihydroxy-L-phenylalanine [26].  Both nonnatural aaRS were evolved from M. 
jannaschii TyrRS. P-acetyl-L-phenylalanine (Figure 1.1) contains a novel ketone 
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functional group not found on any of the other twenty natural amino acids. Using the 
method described above, Wang et al. evolved a mutant TyrRS with > 99.8% fidelity for 
p-acetyl-L-phenylalanine. The high activity of this mutant TyrRS was also demonstrated 
when they were able to express and purify 3.6 mg of a protein containing p-acetyl-L-
phenylalanine from 1 liter of E. coli culture (compared with 9.2 mg/L with a when using 
wild type TyrRS) [25]. Furthermore, they labeled the nonnatural amino acid containing 
protein by covalently attaching a fluorescein hydrazide to the ketone group in vitro. They 
also hypothesized that proteins with unique chemical functions could be generated by 
using the ketone containing amino acid. A nonnatural aaRS derived from M. jannaschii 
TyrRS was evolved that had specificity for 3,4-dihydroxy-L-phenylalanine (L-DOPA) 
[26].  Using this mutant TyrRS, Alfonta et al. expressed 1 mg/L of a L-DOPA 
incorporated protein (compared to 5.6 mg/L with a wild type TyrRS). L-DOPA 
incorporated protein is beneficial because it can also be labeled in vitro by using the 
chemical properties of the nonnatural amino acid. It can also be used to study and capture 
transient protein-protein interactions. Umeda et al. was able to show the dimerization of a 
sortase A protein from Staphylococcus aureus by using L-DOPA to site-specifically 
crosslink the weak dimer complex [27]. 
In addition to p-acetyl-L-phenylalanine and 3,4-dihydroxy-L-phenylalanine, more 
than 30 other nonnatural amino acids have also been incorporated into proteins using this 
technique [1]. For example, a p-azidophenylalanine incorporated human superoxide 
dismutase-1 enzyme was site-specifically attached to a PEG group (PEGylation) [28]. 
This can be used to design new therapeutic proteins with improved solubility and 
increased serum half-life [29]. Bose et al. was able to photo-regulate the DNA binding 
affinity of a protein by incorporating a nonnatural amino acid [30]. An isoleucine in a 
catabolite activator protein (CAP) was replaced with the nonnatural amino acid 
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phenylalanine-4-azobenzene. Upon stimulation with UV-light, phenylalanine-4-
azobenzene converted from a trans to a cis configuration. As a result, the mutant CAP’s 
binding constant drop by almost four folds. Another example is the use of the nonnatural 
amino acid p-iodo-L-phenylalanine to help determine the crystal structure of a protein. A 
phenyalanine in bacteriophage T4 lysozyme was replaced with p-iodo-L-phenylalanine. 
The resulting protein was purified and its structure determined with much greater ease 
than the wild type protein which did not contain p-iodo-L-phenylalanine [31]. These 
examples demonstrate the vast number of applications for site-specifically incorporating 
nonnatural amino acids into proteins.  
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Figure 1.4: A genetic library is created containing random mutations in the aminoacyl-
tRNA synthetases’s active site. These plasmids are cloned into cells who are 
then subjected to several rounds of positive and negative screening in order 
to identify mutants capable of recognizing the nonnatural amino acid 
without recognizing the natural amino acid. The plasmid is isolated from 
surviving clones and then sequenced. Normally, upwards of 108 clones must 
be screened in order to identify a few mutants. (Adobe Flash CS5) 
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1.3 SITE-SPECIFIC INCORPORATION IN MAMMALIAN CELLS 
Nowak was the first to apply the stop codon suppression method of nonnatural amino 
acid incorporation to a mammalian system. Suppressor tRNAs were chemically charged 
with nonnatural amino acids and injected into a Xenopus oocyte. An mRNA construct 
containing an amber codon was also injected into the cell. Several nonnatural amino acids 
were added into ion channels using this technique [22]. However, only very small 
amounts of nonnatural amino acids can be incorporated this way since the suppressor 
tRNAs cannot be regenerated (recharged). Sakamoto et al. overcame this limitation when 
he used a mutant E. coli TyrRS to enzymatically charge a Bacillus stearothermophilus 
tyrosyl-tRNA derived suppressor tRNA within a mammalian cell [32]. Introduction of 
this orthogonal pair in CHO-Y cells was used to incorporate 3-iodo-L-tyrosine in 
response to an amber stop codon. Two amino acids were changed in the E. coli TyrRS’s 
active site to create a mutant that could recognize preferentially recognize 3-iodo-L-
tyrosine over tyrosine (95% efficiency). 
Schultz’s group has also evolved several nonnatural aaRS. A survival assay (Figure 
1.4) was used to screen 108 variations of E. coli TyrRS that contained random mutations 
in its active site [33]. They were able to evolve five different nonnatural aaRS that are 
specific (>99.8%) for p-acetyl-L-phenylalanine, p-benzoyl-L-phenylalanine, p-azido-L-
phenylalanine, O-methyl-L-tyrosine, and p-iodo-L-phenylalanine. An E. coli tyrosyl-
tRNA derived suppressor tRNA was paired with the nonnatural aaRS and introduced into 
yeast cells. As a result, a nonnatural amino acid could be incorporated in response to a 
stop codon. Wang et al. also demonstrated that these yeast evolved pairs could be used in 
mammalian systems. HeLa, mouse hippocampal neuron, and HEK293T cells were able to 
incorporate O-methyl-L-tyrosine in response to an amber stop codon when provided with 
the nonnatural aaRS and suppressor tRNA pair [34]. Finally, they showed that replacing a 
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tyrosine with O-methyl-L-tyrosine in a voltage-dependent K+ channel greatly decreased 
the inactivation of the channel. P-acetyl-L-phenylalanine and p-benzoyl-L-phenylalanine 
were also successfully incorporated into a protein in mammalian cells 
(HEK293T/HEK293S) by using the yeast evolved pairs [35]. These ketone containing 
nonnatural amino acids were incorporated into two G protein-coupled receptors and 
subsequently labeled with fluorescein hydrazide.  
An orthogonal pair from Bacillus subtilis was used to genetically encode a nonnatural 
amino acid, 5-hydroxy-L-tryptophan, in HEK293T cells [36]. The bacterial pair from B. 
substilis is already orthogonal in mammalian cells, but Zhang et al. had to mutate the 
tryptophan-tRNA sequence in order to improve its in vivo transcription. One residue 
within the tryptophan-tRNA synthetase (TrpRS) was mutated resulting in a mutant 
TrpRS with >97% specificity for 5-hydroxy-L-tryptophan. The fluorescence properties of 
a bacteriophage T4 fibritin (foldon) was then altered when a tryptophan was substitute for 
5-hydroxy-L-tryptophan.  
 Although many different types of nonnatural amino acids have been successful 
incorporated into a protein in prokaryotic systems, only a fraction of them have been 
incorporated in mammalian cells. The development of additional pairs will require 
substantial amounts of time and effort in order to either rationally design a nonnatural 
aaRS [36] to evolve one [37]. Since each pair can only be used to incorporate one 
nonnatural amino acid, in order to expand their application in mammalian cells more 
pairs will have to be developed.  
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1.4 OVERVIEW AND SPECIFIC AIMS 
1.4.1 Overview 
Site-specific incorporation of nonnatural amino acids is a powerful tool in the 
study and engineering of proteins. Orthogonal pairs consisting of a suppressor tRNA and 
nonnatural aaRS can be used to incorporate large amounts of nonnatural amino acids into 
proteins in response to the amber stop codon. Genetic encoding allows the site-specific 
incorporation of the nonnatural amino acid within a protein. This prevents the global 
incorporation that is seen when using residue-specific techniques. However, engineering 
a nonnatural aaRS through rationale design or directed evolution is a difficult process. 
Thus far, less than a dozen nonnatural aaRS have been evolved for use in mammalian 
cells. On the other hand, a plethora of M. jannaschii derived nonnatural aaRS  [23, 26, 
38] have been designed but cannot be used in an eukaryotic system due to non-
orthogonality of the pair [39]. We seek to develop a strategy of switching the species 
specific identity and orthogonality of the previously evolved M. jannaschii nonnatural 
tRNA/aaRS pairs. This approach can be used to easily develop more mammalian useable 
pairs and incorporate more types of nonnatural amino acids. To our best of our 
knowledge, there has not been an engineered aaRS with altered specificity for both its 
tRNA and amino acid substrates. Our methodology would change the target specificity of 
M. jannaschii tyrosyl-tRNA synthetase so that it could aminoacylate a non-cognate tRNA 
with a nonnatural amino acid in vivo. The following specific aims will detail our 
approach in the design and creation of a nonnatural pair.   
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1.4.2 Specific Aim 1: Design and express a mammalian-orthogonal amber codon 
suppressing tRNA   
Archaea and eukaryotic tyrosyl-tRNA and tyrosyl-tRNA synthetases are 
orthogonal to E. coli pairs but not to one another [24, 40].  Schimmel’s group has made 
pioneering discoveries in how acceptor stem sequences can determine the amino acid and 
species identity of a tRNAs [40, 41].  We seek to engineer an amber codon suppressing 
tRNA, derived from M. jannaschii tyrosyl-tRNA that is orthogonal in mammalian cells. 
Various designs with mutations in the anticodon and acceptor stem regions will be 
evaluated based on orthogonality and functionality (suppression efficiency). Different 
plasmid designs will also be tested to identify the most optimal method for expressing 
archaea derived tRNA genes in mammalian cells. 
 
1.4.3 Specific Aim 2: Engineer a mutant M. jannaschii tyrosyl-tRNA synthetase that 
can charge the tRNA from Specific Aim 1 
An aminoacyl-tRNA synthetase must recognize two specific targets when 
carrying out the aminoacylation reaction: its cognate tRNA and the corresponding amino 
acid. Previous work by other groups and ourselves has shown that the specificity for one 
can be change without affecting the other [40, 42, 43]. We used rationale design in order 
to engineer a mutant synthetase derived from M. jannaschii tyrosyl-tRNA synthetase that 
could aminoacylate our orthogonal tRNA (Specific Aim 1) in a mammalian cell.  Various 
synthetases designs are evaluated based on their aminoacylation activity and optimized 
for expression in mammalian cells. We investigate whether peptide transplantations can 
be used to switch an aaRS’s tRNA specificity without eliminating its activity.  
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1.4.4 Specific Aim 3: Apply the method from Specific Aim 2 to a nonnatural aaRS 
We hypothesize that the tRNA specificity of a mutant M. jannaschii tyrosyl-tRNA 
synthetase can be altered without affecting its amino acid specificity. This would allow us 
to shuttle many M. jannaschii tyrosyl-tRNA synthetase derived nonnatural aaRS that 
have been used to incorporate nonnatural amino acids in proteins in E. coli cells. We will 
use the method developed in Specific Aim 2 to change the orthogonality of a nonnatural 
aaRS. As a result, it should ignore endogenous mammalian tRNAs while recognizing the 
tRNA from Specific Aim 1. These two components complete the orthogonal suppressor 
tRNA/nonnatural aaRS pair that is required for site-specific incorporation. 3,4-
dihydroxy-L-phenylalanine is a nonnatural amino acid that has successfully been 
incorporated in E. coli [26]. A corresponding nonnatural aaRS, evolved from M. 
jannaschii tyrosyl-tRNA synthetase, can recognize 3,4-dihydroxy-L-phenylalanine while 
discriminating against tyrosine. We will test the CP1 substitution on the 3,4-dihydroxy-L-
phenylalanine aaRS and others in order to demonstrate our methodology of shuttling 
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Engineering a Mammalian-Orthogonal Suppressor tRNA 
 
2.1 AN ORTHOGONAL AMBER CODON SUPPRESSING M. JANNASCHII TYROSYL-TRNA 
2.1.1 Introduction 
An orthogonal amber coding suppressing tRNA is a key component in Schultz’s 
method of site-specific nonnatural amino acid incorporation [1]. A nonnatural aminoacyl-
tRNA synthetase (aaRS) can then be used to charge the suppressor tRNA with a 
nonnatural amino acid [2].  Protein translation normally terminates when a stop codon is 
encountered on the mRNA transcript. However, an amino acid charged suppressor tRNA 
can interact with the ribosome complex and allow translation to proceed past the stop 
codon [3]. As a result, the attached amino acid is incorporated into the protein in response 
to the stop codon and downstream codons are also translated. This chapter will focus on 
the design and expression of a tRNA that can suppress amber stop codons in mammalian 
cells. It must also be orthogonal to the host cell’s aaRS. We assess a number of designs in 
order to identify the tRNA with the highest suppression efficiency and orthogonality. 
Chapters 3 and 4 will detail our efforts to create a nonnatural aaRS that can charge our 
suppressor tRNA with a nonnatural amino acid. 
A tyrosyl-tRNA from Methanococcus jannaschii was chosen as the starting 
template for our suppressor tRNA because mutants of the M. jannaschii tyrosyl-tRNA 
synthetase (TyrRS) have been used extensively to incorporate nonnatural amino acids [4]. 
Several existing suppressor tRNAs have already been derived from M. jannaschii tyrosyl-
tRNA but none of them are orthogonal to mammalian TyrRS [5]. This limits their use 
solely to prokaryotic systems. The first base pair in the tyrosyl-tRNA’s acceptor stem has 
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been implicated to be a key determinant in whether aminoacylation can occur between 
tyrosyl-tRNAs/TyrRS from different species [6]. Archaea and eukaryotic tyrosyl-tRNAs 
contain a C1:G72 sequence and can be charged be each other’s TyrRS. However, 
prokaryotic tyrosyl-tRNA acceptor stems have a G1:C72 sequence and is orthogonal to 
archaea and eukaryotic TyrRS (Figure 2.1). The importance of this pair is further 
demonstrated in works done by Quinn et al. [7] when it was shown that an eukaryotic 
TyrRS can no longer recognize and charge a tRNA microhelix after its acceptor stem was 
mutated from C1:G72 to G1:C72. Pioneering work by Schimmel and others have also 
investigated the importance of the acceptor stem sequence in determining the identity of a 
tRNA [8]. These studies suggest that the recognition of M. jannaschii tyrosyl-tRNA by 
eukaryotic TyrRS can be reduced by modifying its acceptor stem sequence. 
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Figure 2.1: Secondary structure predictions of tyrosyl-tRNAs from E. coli, M. jannaschii 
and human. All three tRNAs contain a GUA sequence in their anticodon 
region. This allows them to correctly base pair with a TAC codon which 
corresponds to tyrosine in the genetic code. E. coli tyrosyl-tRNA contains a 
G1:C72 sequence in its acceptor stem region and is neither recognized by M. 
jannaschii nor human TyrRS. M. jannaschii and human tyrosyl-tRNA 
contain a C1:G72 sequence and can be charged by the each other’s TyrRS. 
(tRNAscan-SE, UCSC) 
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2.1.2 Results and Discussion 
A gene was first constructed to express a suppressor tRNA in HEK293T cells. 
Sequences from a human tyrosyl-tRNA gene were added to the 5’ and 3’ ends of a M. 
jannaschii tyrosyl-tRNA sequence. The anticodon region of the tRNA was then mutated 
from GTA to CTA which allows it to base pair with an amber stop codon (TAG). Six 
tandem-copies of this construct were cloned into pZeoSV2 (+) (Invitrogen, Carlsbad, 
CA) to make the plasmid 6x_wt-tRNACUA. An orthogonal suppressor tRNA was also 
made in a similar fashion except the acceptor stem contained a G1:72 base pair. Six 
tandem copies of this tRNA constructed were cloned into pZeoSV2 (+) to make the 
plasmid 6x_1bp-tRNACUA (Figure 2.2). 
 
 
Figure 2.2: Sequence of the tRNA in the plasmid 6x_1bp-tRNACUA. A suppressor tRNA 
was first made by changing the anticodon from GUA to CUA. Swapping 
C1:C72 sequence in the acceptor stem with G1:C72 reduces its recognition 
by endogenous synthetases. Sequences were also added to the 5’ and 3’ ends 
of the gene to improve its transcription in HEK293T cells. 
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 To test the suppression efficiency of the tRNA we introduced an amber stop 
codon into a T4 fibritin (foldon) gene at the 68th position.  This mutant gene was then 
cloned into pCDNA3.1 (Invitrogen, Carlsbad, CA) which also contained a sequence for a 
V5 peptide on the C-terminus. HEK293T cells were transfected with a tRNA plasmid and 
the foldon_68TAG plasmid. Cells were harvested 48 hours later and full length foldon 
protein was purified and detected using anti-V5 antibodies (Figure 2.4). Codons after the 
TAG should not be translated into amino acids since translation terminates when the stop 
codon is encountered by the ribosome complex. Full length foldon protein (with a V5 
tag) can only be detected if the cell has a charged suppressor tRNA (Figure 2.3). Full 
length foldon was observed in cells that were transfected with the 6x_wt-tRNACUA 
plasmid suggesting that the HEK293T TyrRS was able to charge it with tyrosine. This 
supports previous studies by others that have demonstrated the aminoacylation of M. 
jannaschii tyrosyl-tRNA by an eukaryotic TyrRS [5]. On the other hand, cells transfected 
with the 6x_1bp-tRNACUA plasmid produced very little full length foldon. This suggests 
that a single base pair swap in the acceptor stem was able to dramatically reduce the 




Figure 2.3: Translation of the mRNA transcription usually terminates when a stop codon 
(i.e. TAG/UAG) is encountered. Only a charged suppressor tRNA can be 
used to ‘suppress’ the stop codon and allow translation to continue. 
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Figure 2.4: Suppression of an amber stop codon in a foldon gene. Expression of full 
length foldon was probed using anti-V5 antibodies that are present on the C-
terminal end if it is completely translated. Co-transfection of HEK293T cells 
with plasmids containing the tRNA and foldon_68TAG plasmids only 
resulted in full length foldon expression when the tRNA contained a C1:G72 
sequence [9].  
Green fluorescent protein (GFP) was also used as a reporter protein since it can be 
detected with UV-light. An amber stop codon (TAG) was introduced into the 40th 
position of a GFP gene and cloned into a plasmid. HEK293T cells were co-transfected 
with the GFP_40TAG and 6x_1bp-tRNACUA plasmids. Fluorescent activated cell sorting 
(FACS) was used to quantify the amount of full length GFP expression. Introduction of 
the TAG into the GFP gene produced only a truncated GFP that was not detectable by 
FACS. Co-transfection with the 6x_1bp-tRNACUA also restored < 1% (Figure 3.5) of full 
length GFP expression indicating that it was not charged by the host’s TyrRS. This 
agrees with the outcomes of the foldon suppression assay. Results from this section 
demonstrate that an orthogonal amber codon suppressing tRNA can be created from M. 
jannaschii tyrosyl-tRNA by manipulating its acceptor stem sequences. 
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2.1.3 Materials and Methods 
Cell Culturing and Transfections 
 Plasmids were amplified by transforming electrically component E. coli TOP10 
cells, grown in LB, and isolated using QIAprep Spin Miniprep Kit (Qiagen, Madison, 
WI). HEK293T cells (ATCC CRL-11268) were cultured in Dulbecco’s Modified Eagle 
Medium (D-MEM) supplemented with 10% (v/v) fetal bovine serum (Atlanta 
Biologicals, #C0136) at 37 ºC in a humidified incubator containing 5% CO2. 
Transfections were performed according to product manual using FuGENE 6 (Roche, 
Indianapolis, IN). Full length GFP was excited at 460-500 nm and detected using a Nikon 
Eclipse TE2000-S microscope equipped with a FITC HyQ filter (Chroma).  
 
Plasmid Construction 
A mutated M. jannaschii tyrosyl-tRNA gene containing changes in the anticodon 







Also included in these oligonucleotides are the 5’ flanking sequences 
5’-AGCGCTCCGGTTTTTCTGTGCTGAACCTCAGGGGACGCCGACAC 
ACGTACACGTC-3’ 
and 3’ flanking sequences from a human tyrosyl-tRNA gene: 
5’-TTTATTATAAATTATCTA-3’ 
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The oligonucleotides were annealed then extended using a Klenow (New England 
Biolabs, Ipswich, MA) enzyme for 30 minutes, according to the product manual. The 
mutant tRNA sequence was amplified by PCR, digested overnight with restriction 
enzymes (NEB) PstI and XhoI. Then it was ligated using T4 DNA ligase (NEB) into a 
plasmid, pZeoSV2 (+) (Invitrogen, Carlsbad, CA), pre-digested with PstI and XhoI. This 
resulting plasmid (1xtRNA) was used as a template to create our six-tandem copy 
plasmid. To create the six-tandem copy plasmid, the mutant tRNA gene was first 
amplified by PCR using the primers  
5’-GGGGTACCAGCGCTCCGGTTTTTCTGTG-3’ 
5’-GGGTACCTAGATAATTTATAATAAATGGTGCGGCGGG-3’ 
The PCR product was then cleaned using a QIAprep Kit (Qiagen, Madison, WI), digested 
with restriction enzymes KpnI and ligated with T4 DNA ligase into a 1xtRNA plasmid 
predigested with KpnI creating a 2xtRNA plasmid. Another copy of the mutant tRNA 
gene was amplified by PCR using the primers  
5’-GGAATTCAGCGCTCCGGTTTTTCTGTG-3’ 
5’-GGGAAGCTTGGGCCCTCTAGACTCGAG-3’ 
The resulting PCR product was cleaned, digested with restriction enzymes EcoRI. After 
purification, the product was ligated using T4 DNA ligase into a 2xtRNA plasmid pre-
digested with EcoRI to create a 3xtRNA plasmid. Finally, to create the six-tandem copy 




The resulting product was purified, digested with the restriction enzymes NheI and 
HindIII, purified and then ligated using T4 DNA ligase into a 3xtRNA plasmid pre-
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digested with NheI and HindIII. The final 6xtRNA construct was confirmed by DNA 
sequencing (University of Texas Core Facility). 
The 40th codon of a green fluorescent protein (GFP) gene under control of a CMV 
promoter in a mammalian expression vector (pLit) was mutated to an amber codon 
(TAG) using the Quikchange II Site-Directed Mutagenesis Kit (Stratagene) according to 
the product manual. The identity of the resulting GFP-40TAG plasmid was confirmed by 
DNA sequencing (University of Texas Core Facility). 
The foldon-68TAG plasmid, which was used to express the bacteriophage T4 
fibritin (foldon) domain in HEK293T cells, was constructed by inserting the PCR-
amplified gene fragment into the pCDA3.1-V5-His-TOPO vector (Invitrogen, Carlsbad, 
CA). Plasmid foldon-68TAG, which contains an amber stop codon in its 68th position, 
was constructed by site directed mutagenesis by using the QuikChangeXL (Stratagene,) 
method and the corresponding HPLC-purified primers. 
 
Harvest and Lysis of HEK293T Cells 
 72 hours after transfection, HEK293T cells were detached by physical scrapping 
and collected by centrifugation at 1000xg. A passive lysis buffer (Promega) 
supplemented with a complete protease cocktail inhibitor (Roche, Indianapolis, IN) was 
used to lyse the collected cells on ice for 30 minutes. A soluble protein fraction was 




The soluble protein fractions were separated by 12% SDS-PAGE and transferred 
onto an Immobilon PVDF membrane (Millipore) in a transfer buffer (48 mM Tris, 39 
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mM glycine, 20% methanol (v/v), pH 9.2) using a BioRad Semi-Dry Blotter. The 
membrane was then probed for full length foldon expression using an anti-V5 antibody 
(Invitrogen, Carlsbad, CA) and a goat anti-mouse alkaline phosphatase conjugated 
secondary antibody (Bio-Rad, Hercules, CA). The bands were visualized using a 
chemiluminscent reagent, PhosphaGlo AP (KPL) on a BioMax Light Film (Eastman 
Kodak Co., Rochester, NJ). 
 
FACS Analysis 
  A BD FACSCalibur flow cytometer was used to gate 10,000 cells based on 
forward and side scatter. Each cell was then excited with 488 nm light and its resulting 
emission detected with an FL-1 filter (515-545 nm). Positive fluorescent populations 
were gated based on negative controls and analyzed using the computer software 













2.2 EXPRESSING AN ARCHAEA TRNA GENE WITH THE HUMAN H1 PROMOTER 
2.2.1 Introduction 
Our next focus was on improving the transcription efficiency of the M. jannaschii 
tRNA gene in HEK293T cells. Schultz’s method of site-specific nonnatural amino 
incorporation is limited by the amount aminoacylated suppressor tRNA present in the 
cell. Our previous design consisted of multiple copies of the archaea tRNA gene flanked 
by sequences taken from a human tyrosyl-tRNA gene [9]. However, the transcriptional 
regulation of tRNA genes differs greatly between eukaryotic and archaea species. 
Sequences within eukaryotic tRNA genes, such as internal promoters, are usually 
required in order to initiate transcription [10]. A single type of RNA polymerase is used 
to transcribe both mRNA and tRNA in archaea cells while eukaryotic cells uses a 
different RNA polymerase for each [11]. Another key difference occurs in the post-
transcriptional processing of the tRNA genes. The tRNA gene that is contained in 
6x_1bp-tRNACUA included a 3’CCA sequence but it has been shown that this is added 
post-transcriptional to the tRNA in eukaryotic cells [12]. All these factors suggest that 
our previous design was an inefficient way of expressing an archaea tRNA gene. 
Wang et al. recently had success in using the human H1 promoter  [13] to express 
an E. coli tyrosyl-tRNA gene in mammalian cells [14]. We reason that a similar approach 
can be used to express our M. jannaschii suppressor tRNA gene. A sequence of about 
200 nucleotides, taken from the human H1 RNA gene, is sufficient in size to recruit RNA 
polymerase III and initiate transcription [13]. We constructed an entirely new plasmid 
consisting only of the human H1 promoter and a downstream tRNA gene with an added 
3’ flanking sequence. The multiple-tandem copies design was replaced in favor of a 
single tRNA gene, lacking the 3’ CCA (Figure 2.5). We relied on endogenous post-
transcriptional mechanisms to add this sequence. Using this plasmid we tested its ability 
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to express functional tRNA by using it to express a non-orthogonal suppressor tRNA (wt-
tRNACUA). 
 
2.2.2 Results and Discussion 
We designed a suppression assay to test the ability of the human H1 plasmid 
design to express tRNA genes. A gene for M. jannaschii tyrosyl-tRNA was first cloned 
downstream of the human H1 promoter (Figure 2.5). The anticodon region of this tRNA 
was modified from GUA to CUA to make H1_wt-tRNACUA. Another plasmid was used 
to harbor and express a gene for green fluorescent protein (GFP) that contained an amber 
stop codon in the 40th position (GFP_40TAG). This is similar to the suppression assays 
discussed in the previous section when we calculate suppression efficiency based on the 
expression of full length protein. The total amount of full length GFP was detected by 
UV-light and quantified using fluorescent activated cell sorting (FACS). If the tRNA was 
non-orthogonal then it should be easily aminoacylated by endogenous TyrRS. The stop 
codon in the GFP gene would only be suppressed by an aminoacylated suppressor tRNA, 




Figure 2.5: Comparing the 6x_wt-tRNACUA and H1-wt-tRNACUA plasmid constructions. 
The six-tandem approach is discarded in favor of an upstream human H1 
promoter. A 3’ flanking sequence was also used to terminate transcription. 
tRNA gene sequences are identical except in the 3’ CCA tail. 6x_wt-
tRNACUA contains the sequence but H1_wt-tRNACUA does not. 
HEK293T cells were transfected with the GFP_40TAG and H1_wt-tRNACUA 
plasmids. A plasmid harboring a wild type GFP gene was also used as a positive control. 
GFP expression was monitored using UV-light and quantified 72 hours after transfection 
using FACS analysis (Figure 2.6). Addition of the amber stop codon into the GFP gene 
resulted in almost no full length GFP expression. When H1_wt-tRNACUA was present in 
the cell, it was recognized and charged by HEK293T TyrRS. As a result, a functional 
suppressor tRNA was generated that was able to restore a third of the full length GFP 
expression. Finally, to show that the observed fluorescence was a result of GFP 
expression we used anti-GFP antibodies to confirm its identity (Figure 2.7). The results 
of our studies show that the human H1 promoter can be used to transcribe high levels of 
an archaea tRNA gene. This method should allow us to produce more nonnatural amino 




Figure 2.6: Almost no full length GFP can be detected after an amber stop codon is 
introduced into the gene. When wt-tRNACUA is also present in the cell, 
endogenous TyrRS can recognize and charge it with tyrosine. This creates a 
functional suppressor tRNA that can be used to suppress the amber stop 
codon resulting in full length GFP. Our M. jannaschii tyrosyl-tRNA derived 
gene can be efficiently expressed using the H1 promoter. (Cyflogic) 
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Figure 2.7: Detection of full length GFP with anti-GFP antibodies. HEK293T cells were 
transfected and harvested 72 hours later. (1) GFP_40TAG (2) GFP_40TAG 
and H1_wt-tRNACUA. A band that corresponded to the molecular weight of 
GFP (~27 kDa) was detected in cells transfected with the nonnatural 
suppressor tRNA. 
 
2.2.3 Materials and Methods 
Cell Culturing and Transfections 
 All plasmids were amplified in E. coli TOP10 cells and isolated using Qiagen’s 
Miniprep Kits. HEK293T cells (ATCC CRL-11268) were cultured in Dulbecco’s 
Modified Eagle Medium (D-MEM) supplemented with 10% (v/v) fetal bovine serum 
(Atlanta Biologicals, #C0136) at 37 ºC in a humidified incubator containing 5% CO2. 
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Transfections were performed according to product manual using FuGENE HD (Roche, 
Indianapolis, IN). Full length GFP was excited at 460-500 nm and detected using a Nikon 
Eclipse TE2000-S microscope equipped with a FITC HyQ filter (Chroma).  
 
Construction of the GFP_40TAG Plasmid 
A commercially available plasmid p-EGFPN1 (Clontech) was used to express a 
gene for EGFP using a CMV promoter. The 40th codon in the EGFP gene was mutated 
from TAC to TAG using site-directed mutagenesis (SDM) using primers designed by 
Stratagene’s online primer design program  
5’-GCGAGGGCGAGGGCGATTAGACCTACGGCAAGC-3’ 
5’-GCTTGCCGTAGGTCTAATCGCCCTCGCCCTCGC-3’ 
The QuickChange II Site-Directed Mutagenesis Kit was purchased from Stratagene 
(Stratagene, Agilent Technologies, Inc., Santa Clara, CA), and site-directed mutagenesis 
was completed according to the provided protocol. Plasmids were sequenced by the 
University of Texas at Austin ICMB DNA Sequencing Facility. The new plasmid was 
termed GFP_40TAG. 
 
Construction of the Human H1 Promoter tRNA Plasmid (H1_wt-tRNACUA) 
The MCS-1 region from a commercially available plasmid, pTRE-TIGHT-BI 
(Clontech) was removed by digested the plasmid with restriction enzymes KpnI and 





were annealed, digested with KpnI and EcoRI. The digested insert was then ligated using 
DNA T4 Ligase into the pre-digested p-TRE-TIGHT-BI to form p-TRE-TIGHT-T7. 
Next, oligonucleotides containing the sequence for the human H1 promoter were 











The resulting product was digested with restriction enzymes KpnI and BglII and ligated 
into a pre-digested p-TRE-TIGHT-T7 plasmid to make pT7-H1.  
 
FACS Analysis 
  A BD FACSCalibur flow cytometer was used to gate 10,000 cells based on 
forward and side scatter. Each cell was then excited with 488 nm light and its resulting 
emission detected with an FL-1 filter (515-545 nm). Positive fluorescent populations 




2.3 EVALUATING THE ORTHOGONALITY OF VARIOUS M. JANNASCHII TYROSYL-TRNA 
DERIVED SUPPRESSOR TRNAS 
2.3.1 Introduction 
Studies by Schimmel and others have identified an ‘operational RNA code’ that 
exists within the sequences of a tRNA’s acceptor stem [8]. Aminoacyl-tRNA synthetases 
(aaRS) recognize the base pairs in these regions in order to identify their cognate tRNA. 
For example, Schimmel has shown that the first base pair in the acceptor stem of tyrosyl-
tRNA determines whether cross-species aminoacylation occurs. Archaea and eukaryotic 
tyrosyl-tRNA synthetase (TyrRS) charge each other’s tyrosyl-tRNA (C1:G72) but not 
prokaryotic tyrosyl-tRNA (G1:C72) [6]. We showed in a previous section that mutating 
M. jannaschii tyrosyl-tRNA’s G1:C72 to C1:G72 allows it to evade recognition by 
eukaryotic TyrRS. E. coli tyrosyl-tRNA is orthogonal in mammalian cells and differs 
from M. jannaschii tyrosyl-tRNA in the first three base pairs of its acceptor stem. In this 
section we investigate the effects on orthogonality by modifying additional pairs within 
the M. jannaschii tyrosyl-tRNA’s acceptor stem. The CP1 region has been shown to 
directly interact with these sequences and additional mutations could affect the folding 
and structure in that region. The crystal structure of the M. jannaschii tyrosyl-tRNA in 
complex with its cognate TyrRS also shown that the TyrRS interacts directly with other 
sequences in the acceptor stem in addition to the C1:G72 pair [15].  
The ability to rapidly test the orthogonality of various tRNA constructs is a huge 
benefit in using the human H1 promoter plasmid to express a tRNA gene. PCR and 
cloning steps are greatly reduced since only one copy of the tRNA gene was required as 
opposed to six or more copies. Using this plasmid, we tested the effects on orthogonality 
of additional acceptor stem modifications. 
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2.3.2 Results and Discussion 
 
Figure 2.8: Comparing the acceptor stem sequences of various tRNA constructs. Wt-
tRNACUA is known to be non-orthogonal while E. coli tyrosyl-tRNA is 
orthogonal. Each tRNA gene was cloned into a plasmid, downstream of the 
human H1 promoter. We use a suppression assay to evaluate each design 
based on its recognition by HEK293T TyrRS (pknotsRG, BiBiServ) 
Once again, a suppression assay was used to measure the orthogonality of each 
tRNA design. We co-transfected HEK293T cells with a mammalian expression plasmid 
that contained a gene for GFP_40TAG and a plasmid containing one of four tRNA 
designs (Figure 2.8). The tRNA plasmid was constructed as described in the previous 
section: an upstream human H1 promoter followed by a tRNA gene which has its 3’CCA 
tail replaced with a 3’ flanking sequence from a human tyrosyl-tRNA gene. A single 
plasmid transfection with a mammalian expression plasmid containing a gene for GFP 
was also used as a positive control. And a single plasmid transfection with a gene for 
GFP_40TAG was used as a negative control. 
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Figure 2.9: Assessing the orthogonality of various tRNA constructs in HEK293T cells. 
72 hours after transfection FACS was used to quantify population of 
fluorescent cells. Wt-tRNACUA was non-orthogonal as expected. However 
both 2bp-tRNACUA and 3bp-tRNACUA were less orthogonal than 1bp-
tRNACUA even though they had sequences that more closely matched E. coli 
tyrosyl-tRNA’s acceptor stem. 
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Full length GFP was detected in HEK293T by UV-light and quantified using 
FACS (Figure 2.9). Large amounts of the protein are seen in cells after transfection with 
the GFP plasmid. This is dramatically reduced when an amber stop codon (TAG) was 
introduced into the gene. Transcription of the GFP_40TAG gene should still occur as 
normal but translation would halt once the ribosome complex encounters an amber stop 
codon. Since no full length GFP is produced, no fluorescence is observed. Co-
transfections of HEK293T cells with the GFP_40TAG and H1_wt-tRNACUA plasmids 
restored nearly a third of the full length GFP. Wt-tRNACUA does not contain any acceptor 
stem modifications and thus is not orthogonal in mammalian cells as previously reported 
[5]. Endogenous aaRS in the HEK293T cells recognized and aminoacylated the 
suppressor tRNA. A change in the first base pair of the acceptor stem from C1:G72 to 
G1:C72 (1bp-tRNACUA) once again resulted in very low amounts of full length GFP 
(~1.7%). To our surprise, additional mutations in the acceptor stem sequence actually 
increased the expression of full length GFP. Previous work by other labs have 
demonstrated that E. coli tyrosyl-tRNA is orthogonal in mammalian cells [14]. Due to the 
important of sequences within the acceptor stem in determining tRNA identity, we 
expected 3bp-tRNACUA to be the most orthogonal since the first four base pairs in its 
acceptor stem (G1:C72, G2:C71, T3:A70,G4:C69) are identical to E. coli tyrosyl-tRNA. 
However, both it and 2bp-tRNACUA increased full length GFP expression by several 
magnitudes. A search of known human tRNA sequences revealed that two leucyl-tRNA 
genes also contain the same acceptor stem sequences as 3bp-tRNACUA (G1:C72, G2:C71, 
U3:A70, and A73). Thus it could be possible that endogenous leucyl-tRNA synthetases 
are recognizing our tRNA and charging it with leucine. Further work will need to be done 
in this area. 
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Finally we wanted to test the functionality of the 1bp-tRNACUA to ensure that it is 
folding properly in vivo. Low full length GFP expression infers that the suppressor tRNA 
was not aminoacylated by endogenous aaRS. Other than orthogonality, non-
aminoacylation of the tRNA could also suggest that it is not functional or improperly 
folded. Therefore, we transfected HEK293T cells with the plasmids GFP_40TAG, 
H1_1bp-tRNACUA and a mammalian expression plasmid containing the gene for an E. 
coli TyrRS. E.coli TyrRS has been shown to preferentially recognize and charge tyrosyl-
tRNAs mini-helices containing the G1:C72 base pair [6]. If 1bp-tRNACUA is orthogonal 
and functional, then the E. coli TyrRS should recognize and aminoacylate it, restoring the 
expression of full length GFP. 72 hours after transfection, cells were harvested and the 




Figure 2.10: An amber stop codon in the GFP gene results in almost no detectable full 
length GFP. Only a charged suppressor tRNA can suppress the stop codon. 
1bp-tRNACUA cannot be recognized by mammalian TyrRS (orthogonal) but 
is charged by E. coli TyrRS. This demonstrates that 1bp-tRNACUA is 
expressed, processed, and folded correctly.  
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The addition of E. coli TyrRS in HEK293T cells restored a significant amount of 
full length GFP expression. If 1bp-tRNACUA was not functional, then we should expect to 
see a similar amount of full length GFP when E. coli TyrRS was present or absent.  The 
non-orthogonal wt-tRNACUA was chosen as a positive control since it represented the 
maximum amount of functional suppressor tRNA that could be generated by human H1 
promoter plasmid. When E. coli TyrRS was present, the amount of full length GFP 
increased to was almost 75% of the control. This suggests that the 1bp-tRNACUA was 
readily aminoacylated by E. coli TyrRS and then able to suppressor the amber stop codon 
in the GFP gene. Our investigations in this chapter support previous results that 
demonstrate the importance of the G1:C72 or C1:G72 in determining species specific 
identify of the tyrosyl-tRNA [6]. We were able to engineer an orthogonal amber codon 
suppressor tRNA for use in HEK293T cells. This completes the first component required 
for site-specific incorporation of nonnatural amino acids. The next two chapters will 
concentrate on our engineering of the corresponding nonnatural aaRS that can be paired 
with 1bp-tRNACUA. 
 
2.3.4 Materials and Methods 
Cell Culturing and Transfections 
 Plasmids were amplified by transforming electrically component E. coli TOP10 
cells, grown in LB, and isolated using QIAprep Spin Miniprep Kit (Qiagen, Madison, 
WI). HEK293T cells (ATCC CRL-11268) were cultured in Dulbecco’s Modified Eagle 
Medium (D-MEM) supplemented with 10% (v/v) fetal bovine serum (Atlanta 
Biologicals, #C0136) at 37 ºC in a humidified incubator containing 5% CO2. 
Transfections were performed according to product manual using FuGENE 6 (Roche, 
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Indianapolis, IN). Full length GFP was excited at 460-500 nm and detected using a Nikon 
Eclipse TE2000-S microscope equipped with a FITC HyQ filter (Chroma).  
 
Construction of H1_1bp-tRNACUA, H1_2bp-tRNACUA, H1_3bp-tRNACUA 
Two oligonucleotides for the 1bp-tRNACUA gene was were annealed, extended 







The PCR product was then digested with BglII and PstI and ligated into a pre-digested 
pT7-H1 (described above) plasmid to create 1bp-tRNACUA plasmid.  
H1_2bp-tRNACUA was created in a similar fashion using the following oligonucleotides 
















Constructing the E. coli TyrRS Plasmid 




The PCR product was digested with restriction enzymes XbaI and BamHI (New England 
Biolabs, Ipswich, MA) and ligated using T4 ligase into a pre-digested pEF6-V5 
(Invitrogen, Carlsbad, CA) to express E. coli TyrRS in HEK293T cells. 
 
FACS Analysis 
 A BD FACSCalibur flow cytometer was used to gate approximately 10,000 cells 
based on forward and side scatter. Each cell was then excited with 488 nm light and its 
resulting emission detected with an FL-1 filter (515-545 nm). Positive fluorescent 
populations were gated based on negative controls or positive controls and analyzed 
using the computer software Cyflogic v.1.2.1 (CyFlo, Ltd., Turku, Finland). 
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Altering the tRNA Specificity of an Aminoacyl-tRNA Synthetase 
 
3.1 A CP1 SUBSTITUTED M. JANNASCHII TYROSYL-TRNA SYNTHETASE CHARGES 1BP-
TRNACUA 
3.1.1 Introduction 
Chapter two concentrated on our efforts to design and express a functional amber 
codon suppressing tRNA (1bp-tRNACUA) that is orthogonal to mammalian aminoacyl-
tRNA synthetases (aaRS). Now we shift our area of focus to the engineering of an aaRS 
that can charge 1bp-tRNACUA with a nonnatural amino acid. These two components will 
form an orthogonal pair that can be used to genetically encode a nonnatural amino acid in 
response to the amber stop codon [1]. Several nonnatural aaRS have been evolved from 
the M. jannaschii tyrosyl-tRNA synthetase (TyrRS) and are capable of charging M. 
jannaschii tyrosyl-tRNA derived suppressor tRNAs with a nonnatural amino acid [2]. 
However, none of these nonnatural aaRS are not orthogonal in mammalian systems and 
will therefore aminoacylate endogenous tyrosyl-tRNAs. They also interact with a C1:G72 
sequence in the acceptor stem region of their corresponding suppressor tRNA and would 
probably not recognize our 1bp-tRNACUA. In order to complete our pair we will have to 
alter the tRNA recognition of these nonnatural aaRS.  
Schimmel and Wakasugi have previously demonstrated that the tRNA recognition 
of an aaRS can be changed without affecting its amino acid specificity. They constructed 
a mutant human TyrRS by substituting its connective polypeptide 1 (CP1) domain with 
the corresponding amino acids from the Escherichia coli TyrRS. The CP1 substituted 
human TyrRS was able to aminoacylate an E. coli tyrosyl-tRNA in vitro [3]. Their 
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seminal work showed that a TyrRS, which normal recognizes a C1:G72 tRNA can be 
manipulated into charging a G1:C72 tRNA. 
 
 
Figure 3.1: Crystal structure alignments of TyrRS from human (blue) and M. jannaschii 
(grey). The enzymes share a very similar 3-D structure and only charges 
C1:G72 containing tyrosyl-tRNAs. A CP1 substituted human TyrRS was 
able to charge an E. coli tyrosyl-tRNA which contains a G1:C72 acceptor 
stem sequence [3]. Alignments and images were created with the PyMOL 
Molecular Graphics System (pymol.org) 
Both human and M. jannaschii TyrRS recognize tyrosyl-tRNAs containing a 
C1:G72 sequence while prokaryotic TyrRS recognize G1:C72. Human and M. jannaschii 
TyrRS also share a very similar 3-D crystal structure, especially in the CP1 domain 
(Figure 3.1). Strong structural and functional homology between the two TyrRS suggests 
that a CP1 substitution could also be used to manipulate the M. jannaschii TyrRS into 
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charging a G1:C72 containing tRNA (1bp-tRNACUA). The CP1 switched TyrRS should 
also have increased orthogonality in mammalian systems since its recognition of 
endogenous eukaryotic C1:G72 containing tyrosyl-tRNAs will be reduced. In this chapter 
we will investigate how changes in the CP1 region of M. jannaschii TyrRS affect its 
tRNA specificity. We later hope to apply this approach to some previously evolved 
nonnatural aaRS (evolved from M. jannaschii TyrRS). A functional nonnatural aaRS that 
could recognize our 1bp-tRNACUA would complete the orthogonal pair and can be used to 
genetically incorporate a nonnatural amino acid in a mammalian cell (Chapter 4). 
 
3.1.2 Results and Discussion 
 PyMOL Molecular Graphics System first was used to superimpose the crystal 
structures of the human (PDB: 1N3L) and M. jannaschii (PDB: 1J1U) TyrRS (Figure 
3.1). Based on the similarity in structure, we identified a segment of the M. jannaschii 
TyrRS that corresponded to the human TyrRS’s CP1 domain [3]. These amino acids were 
removed and replaced with an E. coli TyrRS CP1 sequence (Figure 3.2). The gene for 
this CP1 substituted M. jannaschii TyrRS was cloned into pEF6-V5-His6-TOPO 
(Invitrogen, Carlsbad, CA) to make TyrRS_44CP1. 
 
 
Figure 3.2: Alignment of amino acid sequences between M. jannaschii TyrRS and 
TyrRS_44CP1. Amino acids 110-148 were removed from the M. jannaschii 
TyrRS and replaced with amino acids 129-172 from E. coli TyrRS to create 
TyrRS_44CP1. A TyrRS’s CP1 domain directly interacts with the tyrosyl-
tRNA’s acceptor stem region.   
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 If The CP1 substitution affected the M. jannaschii TyrRS in the same way it 
affected the human TyrRS then TyrRS_44CP1 should be able to recognize and charge a 
G1:C72 containing tyrosyl-tRNA. As detailed in Chapter 2, a plasmid (6x_1bp-
tRNACUA) was created to express an orthogonal amber codon suppressing tRNA that was 
derived from M. jannaschii tyrosyl-tRNA. If the tRNA specificity of the TyrRS_44CP1 
was changed as a result of the CP1 swap, then it should be able to recognize the G1:C72 
containing 1bp-tRNACUA. We used a functional suppression assay to assess the activity of 
the TyrRS_44CP1 in HEK293T cells. An amber stop codon was first introduced into the 
68th position of a bacteriophage T4 (foldon) gene and cloned into pCDNA3.1 (Invitrogen, 
Carlsbad, CA). The gene also contained a sequence for a C-terminus V5 peptide that will 
only be translated if the amber stop codon is suppressed. 1bp-tRNACUA is a functional 
suppressor tRNA only if it is charged with an amino acid. This can only occur if 
TyrRS_44CP1 recognizes it since we have previously shown that 1bp-tRNACUA is not 
aminoacylated by endogenous HEK293T aaRS.  
HEK293T cells were transfected with all combinations of three plasmids 
(TyrRS_44CP1, 6x_1bp-tRNACUA, foldon_68TAG). Cells were harvested 48 hours later 
and full length foldon protein was purified and detected using anti-V5 antibodies (Figure 
3.3). Since the gene for the V5 tag is downstream of the amber stop codon, it will only be 




Figure 3.3: Detection of full length foldon protein using anti-V5 antibodies. HEK293T 
cells were transfected and harvested 48 hours later (1) Foldon_68TAG, 
6x_wt-tRNACUA (2) Foldon_68TAG, 6x_1bp-tRNACUA (3) Foldon_68TAG, 
6x_wt-tRNACUA, TyrRS_44CP1 (4) Foldon_68TAG, 6x_1bp-tRNACUA, 
TyrRS_44CP1 (5) Foldon_68TAG, TyrRS_44CP1 (6) Foldon_68TAG 
Neither the presence of the TyrRS_44CP1 nor the 6x_1bp-tRNACUA plasmid was 
able to cause the amber stop codon in the foldon gene to be suppressed (Figure 3.3). This 
demonstrates that each component is orthogonal in HEK293T cells. When both the 
TyrRS_44CP1 and 1bp-tRNACUA were present in the cell, large amounts of full length 
foldon was detected. 1bp-tRNACUA can only suppress the amber stop codon if it is 
charged with an amino acid. This shows that TyrRS_44CP1 can recognize and 




Figure 3.4: Detecting full length GFP using UV-light and anti-GFP antibodies. 
HEK293T cells were transfected and harvested 72 hours later (1) GFP (2) 
GFP_40TAG (3) GFP_40TAG, 6x_wt-tRNACUA,(4) GFP_40TAG, 
TyrRS_44CP1 (5) GFP_40TAG, 6x_wt-tRNACUA, TyrRS_44CP1  
Green fluorescent protein (GFP) was also used as a reporter gene. Full length GFP 
can be easily visualized by UV-light or purified and detected with anti-GFP antibodies. 
An amber stop codon was introduced into the gene by changing the 40th codon from TAC 
(tyrosine) to TAG (amber stop codon). This completely eliminated the expression of full 
length GFP (Figure 3.4). HEK293T cells were also transfected with various 
combinations of the TyrRS_44CP1, 6x_1bp-tRNACUA, and GFP_40TAG plasmids in 
order to measure the suppression efficiency of the TyrRS_44CP1/6x_1bp-tRNACUA pair. 
Combining the GFP_40TAG plasmid with either the 6x_1bp-tRNACUA or TyrRS_44CP1 
plasmid also did not restore the expression of full length GFP, although TyrRS_44CP1 
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and GFP40TAG did result in some increase. This again demonstrates that both 
components are orthogonal to host cell’s endogenous tRNAs and aaRS. Co-transfecting 
HEK293T cells all three plasmids (6x_1bp-tRNACUA, TyrRS_44CP1, and GFP_40TAG) 
was the only case where a larger increase of full length GFP was detected. Analysis using 
fluorescence activated cell sorting (FACS) was also used to measure the suppression 
efficiency of the pair (restored ~1% of full length GFP expression). 
Our results suggest that the E. coli TyrRS CP1 domain can be substituted into M. 
jannaschii TyrRS. This results in a functional TyrRS that can recognize and charge 
tyrosine to a G1:C72 containing tRNA (1bp-tRNACUA). Our approach can be applied to a 
nonnatural aaRS (evolved from M. jannaschii TyrRS) in order to manipulate it into 
charging our 1bp-tRNACUA with a nonnatural amino acid. However, the suppression 
efficiency of the pair is still low (1%) so subsequent sections will first focus on 
increasing the amounts of charged suppressor tRNA in the cell. 
 
3.1.3 Materials and Methods 
Cell Culturing and Transfections 
 All plasmids were amplified in E. coli TOP10 cells and isolated using Qiagen’s 
Miniprep Kits. HEK293T cells (ATCC CRL-11268) were cultured in Dulbecco’s 
Modified Eagle Medium (D-MEM) supplemented with 10% (v/v) fetal bovine serum 
(Atlanta Biologicals, #C0136) at 37 ºC in a humidified incubator containing 5% CO2. 
Transfections were performed according to product manual using FuGENE 6 (Roche, 
Indianapolis, IN). Full length GFP was excited at 460-500 nm and detected using a Nikon 




The 6x_1bp-tRNACUA, foldon_40TAG, and GFP_40TAG constructed in the 
same manner as previously described (Chapter 2.1.3). TyrRS_44CP1 was created by 
replacing the CP1 region of M. jannaschii TyrRS (amino acids 110-148) with the CP1 
region of E. coli TyrRS (amino acids 129-172). The 5’ end of the gene (containing 
sequences for amino acids 1-109) was amplified using the following primers: 
 5’-AAGGATCCACCATGGACGAATTTGAAATGAT-3’ 
5’-ACATTCATATTGCCGAACCACTGGAATTCACTTCCAT-3’ 
The 3’ end (containing amino acids 149-306) was amplified by PCR using primers: 
  5’-AGGGGATTTCGTTCACTGAGGTTATCTATCCAATAATGCA-3’ 
5’-CCCGAATTCTAATCTCTTTCTAATTGGCT-3’ 
Finally, the E. coli CP1 region (amino acids 129-172) was amplified from a wild type E. 
coli TyrRS gene by PCR using the following primers: 
5’-ATGGAAGTGAATTCCAGTGGTTCGGCAATATGAATGT-3’ 
5’-TGCATTATTGGATAGATAACTTCAGTGAACGAAATCCCCT-3’ 
All three PCR framers were combined, denatured for 15 minutes at 85 ºC and elongated 
with a klenow enzyme for 30 minutes at room temperature. The klenow product again 
amplified by PCR, purified, and digested with restriction enzymes HindIII and EcoRI. 
Finally, TyrRS_44CP1 was created by ligating the digested product into a pre-digested 
pEF6-V5-His6-TOPO (Invitrogen, Carlsbad, CA) using T4 DNA ligase (NEB, Ipswich, 
MA).  
 
Harvest and Lysis of HEK293T Cells 
 72 hours after transfection, HEK293T cells were detached by physical scrapping 
and collected by centrifugation at 1000xg. A passive lysis buffer (Promega, Madison, 
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WI) supplemented with a Complete Mini-Protease inhibitor tablet (Roche, Indianapolis, 
IN) was used to lyse the collected cells on ice for 30 minutes. A soluble protein fraction 
was collected by centrifugation at 14,000 krpm for 20 minutes. The resulting solutible 
fraction was subjected to western blot analysis. 
 
Western Blots 
The soluble protein fractions were separated by 12% SDS-PAGE and transferred 
onto an Immobilon PVDF membrane (Millipore) in a transfer buffer (48 mM Tris, 39 
mM glycine, 20% methanol (v/v), pH 9.2) using a BioRad Semi-Dry Blotter. The 
membrane was then probed for full length foldon expression using an anti-V5 antibody 
(Invitrogen, Carlsbad, CA) and a goat anti-mouse alkaline phosphatase conjugated 
secondary antibody (BioRad). The bands were visualized using a chemiluminscent 









3.2 IMPROVING THE SUPPRESSION EFFICIENCY OF THE TYRRS_44CP1/1BP-TRNACUA 
PAIR 
3.2.1 Introduction 
In the previous section we described how a CP1 substitution was used to 
manipulate M. jannaschii TyrRS into charging a G1:C72 containing tyrosyl-tRNA. The 
CP1 swapped TyrRS (TyrRS_44CP1) and an orthogonal amber codon suppressing tRNA 
(1bp-tRNACUA) was able to suppress an amber stop codon in HEK293T cells with an 
efficiency of ~1%. If this approach were applied to a nonnatural aaRS then we would 
only be able to express a very small amount of nonnatural amino acid incorporated 
protein. Therefore our next focus is on the optimization of the TyrRS_44CP1/1bp-
tRNACUA pair.  
Suppression efficiency is directly related to the amount of charged (amino acid 
attached) suppressor tRNA present [4]. To achieve a level >1% we will first have to 
heighten the recognition and interaction between the TyrRS_44CP1 and 1bp-tRNACUA. A 
more active aaRS will result in an increase in the concentration of charged suppressor 
tRNA. We also sought to enhance the transcription and processing of the tRNA gene by 
HEK293T cells. Chapter 2 described how a human H1 promoter resulted in very high 
transcription of the 1bp-tRNACUA gene. The effects of these improvements and more are 
investigated in this section. 
 
3.2.2 Results and Discussion 
Previous studies have suggested that the M. jannaschii TyrRS has very minimal 
interactions with the anticodon region of its cognate tRNA [5]. However, a recently 
published crystal structure of the M. jannaschii TyrRS complexed with its cognate 
tyrosyl-tRNA shows that some residues on the TyrRS do interact with the anticodon 
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region [6]. They also demonstrated that the recognition of a suppressor tRNA derived 
from M. jannaschii tyrosyl-tRNA could be improved by a factor of eight, in vitro, if the 
M. jannaschii TyrRS was mutated in one single residue. Thus, we generated a new 
mutant TyrRS gene derived from M. jannaschii TyrRS by first applying the same 44 
amino acid transplantation as described in the previous section. The 286th amino acid was 
mutated from aspartic acid to arginine as this was shown to increase the recognition of 
the CUA sequence on the suppressor tRNA’s anticodon region [6]. This mutant gene was 
then cloned into pEF6-V5-His6-TOPO (Invitrogen, Carlsbad, CA) to make 
TyrRS_44CP1_R. An ochre stop codon (TAA) was inserted upstream of the V5 and His6 




Figure 3.5: FACS was used to measure and quantify the percentage of positively 
fluorescent cells. TyrRS_44CP1_R resulted in a more than threefold 
increase over background when TyrRS_44CP1 only resulted in a two-fold 
increase. Arg286 enhances the recognition of the suppressor tRNA.  
Once again a functional assay was developed to measure the suppression 
efficiency of the pair. An amber stop codon was introduced into a GFP gene in the 40th 
position to make GFP_40TAG. The tRNA plasmid (6x_1bp-tRNACUA) is described in 
Chapter 2. HEK293T cells were transfected with three plasmids: GFP_40TAG, 6x_1bp-
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tRNACUA, and TyrRS_44CP1_ or TyrRS_44CP1_R. Cells were harvested 72 hours later 
and the total amount of full length GFP was measured using fluorescence activated cell 
sorting (FACS) (Figure 3.5). Some background, due to endogenous charging of the 1bp-
tRNACUA, was observed but when TyrRS_44CP1 was added amount of full length GFP 
nearly doubled. When the C-terminus tags were removed and Arg286 introduced, 
TyrRS_44CP1_R was able to recognize 1bp-tRNACUA almost 50% better. This evidence 
suggests that the Arg286 does enhance interactions between the aaRS and tRNA. In 
addition, the tags are unnecessary and probably only had a negative impact the TyrRS’s 
activity. We also evaluated the effects of adding nuclear localization sequences to both 
the N-terminus and C-terminus ends of the CP1 swapped TyrRS. Sequence alignment of 
all twenty yeast aaRS has shown that fifteen of them contain classical NLS sequences [7]. 
It is also suggested that aminoacylation of the tRNA, inside the nucleus, is required for its 
export [8]. However, addition these NLS peptides resulted in non-functional enzymes 
(data not shown).  
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Figure 3.6: FACS was used to quantify the amount of fluorescent cells. Introducing an 
amber stop codon dramatically reduced the expression of full length, 
functional GFP. Addition of the 1bp-tRNACUA resulted in a increase from 
charging by endogenous aaRS. When both components of the pair are 
present, a suppression efficiency of ~10% is observed. 
Finally, we used the human H1 promoter (Chapter 2) to improve the 
transcription and processing of the 1bp-tRNACUA gene. FACS was used to quantify the 
results of the functional assay (Figure 3.6). The amber stop codon prevented translation 
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of full length GFP and almost no fluorescent cells were observed. The 1bp-tRNACUA, 
while mostly orthogonal, is still recognized to some degree by endogenous aaRS in the 
HEK293T. The pair described in the previous section was able to achieve a suppression 
efficiency of only around 1%. Although our new pair greatly increased the background, 
by almost 250%, we also saw a 1000% increase in suppression efficiency. Chapter 4 will 
detail our efforts to genetically encode some nonnatural amino acids. High suppression 
efficiency will ensure that when we apply our CP1 approach to nonnatural aaRS 
sufficient amounts of incorporated protein can be produced.  
 
3.2.3 Materials and Methods 
Cell Culturing and Transfection of HEK293T Cells 
 Plasmids were amplified by transforming electrically component E. coli TOP10 
cells, grown in LB, and isolated using QIAprep Spin Miniprep Kit (Qiagen, Madison, 
WI). HEK293T cells (ATCC CRL-11268) were cultured in Dulbecco’s Modified Eagle 
Medium (D-MEM) supplemented with 10% (v/v) fetal bovine serum (Atlanta 
Biologicals, #C0136) at 37 ºC in a humidified incubator containing 5% CO2. 
Transfections complexes were formed using FuGENE HD (Roche, Indianapolis, IN). 
Plasmids were diluted in OPTI-MEM (Invitrogen, Carlsbad, CA) and FuGENE HD was 
added at a 2:1 (µL FuGENEHD: µg DNA). After 15 minutes, this was added to 




 GFP_40TAG, TyrRS_44CP1, 6x_1bp-tRNACUA, and H1_1bp-tRNACUA plasmids 
were created as described in previous chapters. To make TyrRS_44CP1_R, the mutant 




The PCR product contains a Kozak initiation sequence as well as the Arg286 mutation. 
Furthermore, an ochre stop codon (TAA) was added to prevent translation of the His6 and 
V5 tags. After digesting with restriction enzymes BamHI and XbaI (New England 
Biolabs, Ipswich, MA) the product was ligated with a DNA T4 ligase into a predigested 
pEF6-V5-His6-TOPO (Invitrogen, Carlsbad, CA) to create TyrRS_44CP1_R.  
 SV40 NLS sequences (PKKKRKV) were added to either the N-terminus or C-









  A BD FACSCalibur flow cytometer was used to gate approximately 10,000 cells 
based on forward and side scatter. Each cell was then excited with 488 nm light and its 
resulting emission detected with an FL-1 filter (515-545 nm). Positive fluorescent 
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populations were gated based on negative controls or positive controls and analyzed 





















3.3 INVESTIGATING OTHER CP1 SUBSTITUTIONS OF M. JANNASCHII TYRRS 
3.3.1 Introduction 
 In the first two sections of this chapter, we showed how a 44 amino acid segment 
from E. coli TyrRS’s CP1 domain can be used to change the tRNA specificity of M. 
jannaschii TyrRS. This CP1 substitution affected the orthogonality of the M. jannaschii 
TyrRS by changing its recognition of the tRNA’s acceptor stem region from C1:G72 to 
G1:C72. Our orthogonal pair, TyrRS_44CP1/1bp-tRNACUA, was able to suppress an 
amber stop codon in HEK293T cells with an efficiency of ~10%. Before we apply this 
methodology to a nonnatural aaRS we wanted to see if we could identify more efficient 
peptide transplantations.  
Wakasugi aligned amino acid sequence of E. coli TyrRS with human TyrRS in 
order to identify the proper CP1 transplantation size [3]. To choose our M. jannaschii 
TyrRS deletions we did a structural alignment of the crystal structures between human 
TyrRS and M. jannaschii TyrRS. In this section, we investigate three differ types of CP1 
transplantation designs. Six are based off the structural alignment between E. coli TyrRS 
and M. jannaschii TyrRS and three based off of their amino acid sequence alignment. We 
also designed two different CP1 transplantations using sequences from Thermus 
thermophilus TyrRS. Each substitution is evaluated using a suppression assay for its 
recognition of 1bp-tRNACUA.  This will allow us to identify an optimal CP1 substitution 
that can be applied to a nonnatural aaRS (Chapter 4). 
 
3.3.2 Results and Discussion 
 In total, we designed eight CP1 substitutions that took sequences from E. coli and 
Thermus thermophilus TyrRS. TyrRS_44CP1_R was renamed TyrRS_44CP1 since all 
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designs also contained the Arg286 mutation that was shown to enhance recognition of the 
suppressor tRNA. Published crystal structures of the E. coli and M. jannaschii TyrRS 
revealed that both enzymes use a Rossmann-fold structural motif in order to bind the 
ATP [6, 9]. A region designated as the CP1 domain divides the six beta strands of the 
Rossmann fold into two parts and is involved in both dimerization as well as interacting 
directly with the tRNA’s acceptor stem sequences. Alignment of the crystal structures 
between the E. coli (pdb.org 1X8X) and M. jannaschii TyrRS (pdb.org 1J1U) were used 
to design six E. coli CP1 swapped mutants: TyrRS_36CP1, TyrRS_39CP1, 
TyrRS_39CP1_2, TyrRS_42CP1, TyrRS_44CP1, and TyrRS_fullCP1. Next we used 
sequence alignment (CLUSTAW, Bioworkbench, SDSC) between the amino acids of the 
two TyrRS to design another three CP1 transplanted mutants: TyrRS_29RED, 
TyrRS_34RED, and TyrRS_38RED. The N-terminus of the CP1 swap are similar to the 
mutants designed with structural homology, however we choose the C-terminus based on 
a RED pattern that is shared by both enzymes. Finally, the crystal structure of T. 
thermophilus TyrRS is published and available [10]. We used structural alignment 
between it and the M. jannaschii TyrRS to design two final CP1 substituted mutants: 




Figure 3.7: Aligning the amino acid sequences of the various CP1 transplanted mutants. 
Inserted CP1 domains are shown in black. Six used sequences from E. coli 
TyrRS while two were taken from T. thermophilus TyrRS. Each was tested 
for their ability to charge 1bp-tRNACUA in HEK293T cells. (Bioworkbench, 
SDSC) 
 A suppression assay was used to evaluate the activity of each CP1 substituted M. 
jannaschii TyrRS for our suppressor tRNA (1bp-tRNACUA). An amber stop codon was 
introduced into the 40th position of a GFP gene to make the plasmid GFP_40TAG. In 
Chapter two we described our design and creation of H1_1bp-tRNACUA, which can 
express an orthogonal amber codon suppressing tRNA in mammalian cells. HEK293T 
cells were transfected with three plasmids: GFP_40TAG, H1_1bp-tRNACUA, and a 
plasmid containing the CP1 swapped TyrRS gene. If the 1bp-tRNACUA can be charged by 
the mutant TyrRS, then a functional suppression tRNA will be present in the cell. As a 
result, the amber stop codon in the GFP_40TAG gene can be suppressed and full length 
GFP expressed. A non-charged 1bp-tRNACUA would not be able to suppress the amber 
stop codon, resulting in the translation of a truncated and non-functional form of GFP.  
 73
 
Figure 3.8: Using a functional assay to test mutant TyrRS’s recognition of 1bp-
tRNACUA. FACS was used to measure the percentage of green fluorescing 
cells 72 hours after transfection. The TyrRS_39CP1_2/1bp-tRNACUA pair 
was able to restore about >6% of full length GFP expression. This is roughly 
a 380% increase over the 1bp-tRNACUA background.  All eight CP1 
substituted TyrRS variations were tested in a similar manner. 
 Figure 3.8 shows the results of our testing of the TyrRS_39CP1_2/1bp-tRNACUA 
pair. Almost no full length GFP was observed when cells were only transfected with 
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GFP_40TAG. Addition of the 1bp-tRNACUA resulted in some increase which is 
consistent with previous results (Chapter 2). However, when both elements of the pair 
were present the amount of full length GFP increased by about 380% (ratio 3.8) 
compared to just 1bp-tRNACUA alone. All of the eight CP1 mutants were evaluated using 
a similar functional assay. E. coli TyrRS used as a positive control since the prokaryotic 
TyrRS recognizes a G1:C72 sequence on its corresponding tyrosyl-tRNA and is able to 
charge 1bp-tRNACUA with high efficiency (Chapter 2). Pairing it up with 1bp-tRNACUA 
resulted in a 13.5 factor increase over 1bp-tRNACUA background (Figure 3.9) 
 
 
Figure 3.9: Ratio of suppression efficiency to tRNA background. A functional assay 
tested the recognition of 1bp-tRNACUA by a CP1 substituted TyrRS. 1bp-
tRNACUA background is always ~1.7% of gated cells. E. coli TyrRS-(EC) 
M. jannaschii TyrRS-(MJ) TyrRS_36CP1-(A) TyrRS_39CP1-(B) 
TyrRS_39CP1_2-(C) TyrRS_42CP1-(D) TyrRS_44CP1-(E) 
TyrRS_fullCP1-(F) TyrRS_29RED-(G) TyrRS_34RED-(H), 
TyrRS_38RED-(I) TyrRS_39tt-(J) TyrRS_45tt-(K) 
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Wild type M. jannaschii TyrRS was also used as a negative control. Not 
surprising, it was still able to recognize the G1:C72 containing 1bp-tRNACUA and 
resulted in a twice the number of fluorescent cells. Some variations were barely 
functional and did not result in any increase: TyrRS_36CP1 and TyrRS_fullCP1. We 
were surprised that a full length CP1 swap (TyrRS_fullCP1) performed so poorly since a 
full CP1 swapped human TyrRS was functional [3]. Poor suppression efficiency could be 
caused by the enzyme misfolding. If the CP1 substitution disrupted the TyrRS’s active 
site then a nonfunctional enzyme would result. None of the T. thermophilus CP1 
transplantations recognized 1bp-tRNACUA very well either. Our understanding of the E. 
coli TyrRS’s CP1 domain is more detailed and probably yielded more rationally designed 
substitutions. The best CP1 substitution was still the TyrRS_44CP1 identified in the 
previous section although TyrRS_39AA_2 also resulted in an almost four times increase 
in fluorescing cells. This concludes our work on changing the orthogonality of M. 
jannaschii TyrRS. The most effective CP1 substitutions can be applied to a nonnatural 
aaRS to change its orthogonality. Manipulating it nonnatural aaRS into charging 1bp-
tRNACUA, without negatively affecting its amino acid recognition can result in functional 
orthogonal nonnatural aaRS. Chapter 4 will focus on our efforts to expand the genetic 
code in mammalian cells by applying this technique to site-specifically incorporate a 
nonnatural amino acid. 
 
3.3.3 Materials and Methods 
Cell Culturing and Transfections 
 All plasmids were amplified in E. coli TOP10 cells and isolated using Qiagen’s 
Miniprep Kits. HEK293T cells (ATCC CRL-11268) were cultured in Dulbecco’s 
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Modified Eagle Medium (D-MEM) supplemented with 10% (v/v) fetal bovine serum 
(Atlanta Biologicals, #C0136) at 37 ºC in a humidified incubator containing 5% CO2. 
Transfections were performed according to product manual using FuGENE HD (Roche, 
Indianapolis, IN). Full length GFP was excited at 460-500 nm and detected using a Nikon 
Eclipse TE2000-S microscope equipped with a FITC HyQ filter (Chroma).  
 
Plasmid Construction 
GFP_40TAG, E. coli TyrRS, TyrRS_44CP1_R, 6x_1bp-tRNACUA, and H1_1bp-
tRNACUA plasmids were created as described in previous chapters. All CP1 transplanted 
mutants were created by PCR in a process similar to the one described in the previous 
section. The chimeric gene was divided into three segments, each one amplified by PCR. 
Finally, a joint gene was also amplified by PCR, digested, and ligated into pEF6-V5-
His6-TOPO (Invitrogen, Carlsbad, CA). Primers are listed for each of the segments based 
























































































  A BD FACSCalibur flow cytometer was used to gate approximately 10,000 cells 
based on forward and side scatter. Each cell was then excited with 488 nm light and its 
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resulting emission detected with an FL-1 filter (515-545 nm). Positive fluorescent 
populations were gated based on negative controls or positive controls and analyzed 
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Genetically Encoding a Nonnatural Amino Acid  
 
4.1 SITE-SPECIFIC INCORPORATION OF 3,4-DIHYDROXY-L-PHENYLALANINE  
4.1.1 Introduction 
 Chapter 1 reviewed several techniques that are currently employed to incorporate 
nonnatural amino acids into a protein. Schultz’s group used pairs that consisted of a 
suppressor tRNA and a corresponding nonnatural aminoacyl-tRNA synthetase (aaRS). 
When introduced into an orthogonal host, these pairs can be used to site-specifically 
incorporate a nonnatural amino acid in response to the amber stop codon (TAG). Dozens 
of nonnatural aaRS have been evolved from Methanococcus jannaschii tyrosyl-tRNA 
synthetase (TyrRS). These pairs have allowed many nonnatural amino acids (>50) to be 
successful incorporated into a protein in prokaryotic cells but only a few (<10) are 
available in mammalian systems [1]. Our project is focused on the development of more 
mammalian useable pairs.  In the previous two chapters, we concentrated our efforts on 
altering the M. jannaschii tyrosyl-tRNA and TyrRS pair so that is orthogonal in 
mammalian cells. In this chapter we use our connective polypeptide 1 (CP1) substitution 
(Chapter 3) to change the orthogonality of several nonnatural aaRS derived from M. 
jannaschii TyrRS. If the CP1 substitution does not affect the nonnatural aaRS’s amino 
acid specificity, then it should be able to charge our 1bp-tRNACUA with a nonnatural 
amino acid.   
3,4-dihydroxy-L-phenylalanine (L-DOPA) is a nonnatural amino acid analog of 
tyrosine (Figure 4.1) that can be used to capture transient protein-protein interactions. 
Our lab has previously incorporated this nonnatural amino acid in response to an amber 
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stop codon in a gene in Escherichia coli cells [2]. We used a M. jannaschii TyrRS 
derived nonnatural aaRS that was previously evolved by Alfonta which specifically 
recognizes L-DOPA. The mutant M. jannaschii TyrRS contained four amino acid 
changes in its active site (Glu26, Leu32, Ser67, Asn70, and Gln167) [3]. First we 
substitute the CP1 domain of this L-DOPA specific aaRS with the CP1 region from E. 
coli TyrRS. We then investigated the ability of this nonnatural aaRS to recognize and 
charge our 1bp-tRNACUA with L-DOPA in HEK293T cells. If its active site is not 
negatively affected by the CP1 substitution, then it should still be able to recognize the 
nonnatural amino acid while discriminating against tyrosine.  Introduction of this 
orthogonal pair can be used to incorporate L-DOPA into protein whenever an amber stop 
codon in present in a gene. 
 
4.1.2 Results and Discussion 
M. jannaschii TyrRS evolved L-DOPA aaRS, L-DOPA_RS, was first modified in 
its connective polypeptide 1 (CP1) region. Amino acids 110-148 were removed from L-
DOPA_RS and replaced with amino acids 129-167 from Escherichia coli TyrRS to 
change its tRNA recognition from C1:G72 to G1:C72 (as discussed in Chapter 3). We 
believe that this will allow the L-DOPA_ 39CP1 to recognize our orthogonal amber 
codon suppressing tRNA, 1bp-tRNACUA, and charge it with L-DOPA. Finally, a reporter 
gene was constructed from green fluorescent protein (GFP) by introducing an amber stop 
codon in the 40th position. After transfection HEK293T cells with all three plasmids, 
expression of full length GFP will only occur if the cell has an aminoacylated suppressor 
tRNA. 1bp-tRNACUA is orthogonal in HEK293T cells (Chapter 2) so only L-
DOPA_39CP1 can recognize and charge it with L-DOPA. We use UV-light to detect full 
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length GFP and used fluorescence activated cell sorting (FACS) to measure the 
population of fluorescent cells.  
 
 
Figure 4.1: (A) Tyrosine and L-DOPA are only different in their side chain. The di-
hydroxy functional group is not found on any of the twenty natural amino 
acids. (B) Primary sequence alignment of the L-DOPA_39CP1 and wild 
type M. jannaschii TyrRS. Glu26, Leu32, Ser67, Asn70, and Gln167 allow 
it to recognize L-DOPA. A CP1 substitution (red) changes its acceptor stem 
recognition from C1:G72 to G1:C72. Arg286 improves its recognition of the 
suppressor 1bp-tRNACUA’s anticodon region. 
HEK293T cells were transfected with the GFP_40TAG, H1_1bp-tRNACUA, and 
L-DOPA_39CP1 plasmids. 96 hours later, the cells were harvested and full length GFP 
was detected using FACS (Figure 4.2). Since only charged suppressor tRNAs can be 
used by the cell to translate full length GFP, the percentage of fluorescent cells was used 
to measure the activity of the L-DOPA_39CP1 for the 1bp-tRNACUA. When cells were 
transfected with the H1_1bp-tRNACUA plasmid only a small amount of suppression 
efficiency was observed. This indicates that the 1bp-tRNACUA is mostly orthogonal, 
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although some recognition by endogenous TyrRS does exist. The addition of the L-
DOPA_39CP1 actually resulted in a more than threefold increase in full length GFP 
expression even when L-DOPA was not present in the growth medium. Unfortunately, 
this shows that the L-DOPA_39CP1 synthetase is still able to recognize tyrosine or some 
other natural amino acid and charge it to the 1bp-tRNACUA. The CP1 substitution is 
affecting the amino acid specificity and reducing the fidelity of the L-DOPA_39CP1 for 
its nonnatural amino acid. When L-DOPA was supplied to the growth medium (5 mM) 
we actually saw a small decrease in the amount of full length GFP. When we 
superimposed the FACS data between when L-DOPA was present or absent we can see 
that that the percentage of lower fluorescing cells actually increased while higher 
fluorescing cells slightly decreased. We can speculate on some of the possible reasons. L-
DOPA could be negatively affecting health of the cells. To dissolve L-DOPA into the 
media we had to reduce the pH of the media to about 7.0 compared to normal media pH 
which is 7.5. As a result, protein expression could be reduced as a result of an unhealthy 
cell. Another possibility is if L-DOPA incorporation into GFP is causing it to be 
degraded more rapidly. Since the FACS data was inconclusive, we decided to use redox-




Figure 4.2: A functional assay was used to assess if L-DOPA_39CP1 could 
aminoacylate 1bp-tRNACUA with L-DOPA in HEK293T cells. L-
DOPA_39CP1 charged 1bp-tRNACUA in the absence of L-DOPA. When L-
DOPA (5 mM) was supplied to the growth media, the cells containing low 
amount of full length GFP increased while cells that had high amounts of 
GFP slightly decreased.  
As before, HEK293T cells were transfected with the three plasmids: 
GFP_40TAG, H1_1bp-tRNACUA, and L-DOPA_39CP1. L-DOPA was also supplied to 
the cells at 5 mM concentration. 96 hours after transfection, full length GFP was purified 
using Ni-NTA agarose beads (Qiagen, Madison, WI). The sample was then concentrated, 
resolved by SDS polyacrylamide gel electrophoresis (PAGE) transferred to a 
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nitrocellulose membrane, and full length GFP was detected using anti-GFP antibodies 
(Figure 4.3). A control lane of over expressed wild type full length GFP was used as a 
positive control.  
 
 
Figure 4.3: Detection of L-DOPA incorporated GFP using anti-GFP antibodies and 
redox-cycling staining. (A) Full length GFP was detected with western blot 
using anti-GFP antibodies. Lane 1 shows wild type GFP. Lane 2 shows the 
L-DOPA incorporated GFP. (B) Shows the results of NBT staining for L-
DOPA. Low signals are enhanced in Lane 2 with Adobe Flash CS5. 
L-DOPA incorporated protein was also detected using nitro blue tetrazolium 
chloride (NBT) in a redox-cycling staining method [2, 4]. A very faint band was detected 
at the molecular weight of GFP (28 kDa). (Figure 4.3) In addition, lower molecular 
weight products were also detected. The staining data corresponds to the western blot 
which seems to full length GFP is present in addition to some lower molecular weight 
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products. This in addition to the FACS data seems to suggest that L-DOPA is being 
incorporated into the GFP.  
 We have demonstrated that the previously evolved M. jannaschii derived L-
DOPA pair can be used in mammalian cells with some modification.  The CP1 
transplantation allowed the nonnatural aaRS to recognize and charge 1bp-tRNACUA. 
When L-DOPA was supplied to the cells, we saw some level of nonnatural amino acid 
incorporation. Since the FACS data does not reveal the identity of the incorporated amino 
acid so we used a staining assay to detect the L-DOPA. Promising results from the both 
genetic and biochemical analysis demonstrated the validity of our technique. This 
approach can be applied to other M. jannaschii derived nonnatural synthetases for rapid 
expansion of the mammalian genetic code. 
 
4.1.3 Materials and Methods 
Cell Culturing and Transfection of HEK293T Cells 
 Plasmids were amplified by transforming electrically component E. coli TOP10 
cells, grown in LB, and isolated using QIAprep Spin Miniprep Kit (Qiagen, Madison, 
WI). HEK293T cells (ATCC CRL-11268) were cultured in Dulbecco’s Modified Eagle 
Medium (D-MEM) supplemented with 10% (v/v) fetal bovine serum (Atlanta 
Biologicals, #C0136) at 37 ºC in a humidified incubator containing 5% CO2. 
Transfections complexes were formed using FuGENE HD (Roche, Indianapolis, IN). 
Plasmids were diluted in OPTI-MEM (Invitrogen, Carlsbad, CA) and FuGENE HD was 
added at a 2:1 (µL FuGENE HD: µg DNA). After 15 minutes, this was added to 




 The construction of the GFP_40TAG and H1-1bp-tRNACUA plasmids is described 
in previous chapters. L-DOPA_39CP1 was generated by replacing amino acid 110-148 in 
the L-DOPA specific aaRS with amino acids 129-167 from E. coli TyrRS. The 5’ 
segment (segment 1) of a previously evolved L-DOPA aaRS gene was amplified from the 
plasmid pAC-DHPhe-6TRN (Gift from Dr. Peter G. Schultz, The Scripps Research 
Institute, La Jolla, CA) with the following primers: 
5’-GCGGATCCGCCACCATGGACGAATTTGAAATGATAAAGAGAA‘3 
5’-ACATTCATATTGCCGAACCAATAAACATATTTTGCCTT-‘3 
A sequence (segment 2) for E. coli TyrRS’s CP1 domain was amplified by PCR using:  
5’-AAGGCAAAATATGTTTATTGGTTCGGCAATATGAATGT-‘3 
5’-ATAACTTCAGCAACCTTTGGCCCCTGATCTTCACGGTTGA-‘3 





The segment 1 forward and segment 2 reverse primers were used to amplify a sequence 
containing segments 1 and 2. Finally, this segment 1_2 joined to segment 3 by PCR using 
segment 1 forward and segment 3 reverse primers. This gene also contained a Kozak 
initiation sequence and the Arg286 mutation. The segment 1_2_3 PCR product was 
digested with BamHI and XbaI (New England Biolabs, Ipswich, MA) and ligated using 




Genetic Incorporation of L-DOPA 
 Each T-75 flask was transfected with 9 µg of GFP_40TAG, 4.5 µg of H1-
1bp_tRNACUA, and 4.5 µg of L-DOPA_39CP1. 12-24 hours after transfection the 
growth media of the cells was replaced with one containing: 4% FBS, 1X MEM Non-
Essential Amino Acids (Sigma Aldrich, St. Louis, MO), 1X Antibiotic/Antimycotic, 5 
mM L-DOPA, and 10 mM sodium ascorbate. Approximately 96 hours after transfection, 
the HEK293T cells were washed 2X with phosphate buffered saline (Sigma Aldrich, St. 
Louis, MO) and collected by centrifugation. Some cells were fixed in a phosphate 
buffered saline containing 4% paraformaldehyde in (USB Corp., Cleveland, OH) and 
stored at 4 ºC for later FACS analysis. Most were rapidly frozen and stored at -80 ºC until 
purification and detection.  
 
FACS Analysis 
  A BD FACSCalibur flow cytometer was used to gate approximately 10,000 cells 
based on forward and side scatter. Each cell was then excited with 488 nm light and its 
resulting emission detected with an FL-1 filter (515-545 nm). Positive fluorescent 
populations were gated based on negative controls or positive controls and analyzed 
using the computer software Cyflogic v.1.2.1 (CyFlo, Ltd., Turku, Finland). 
 
Purifying and Detecting L-DOPA Incorporated GFP 
 Approximately 6 g of frozen HEK293T cells (-80 ºC) were thawed and 
resuspended in 30 mL of lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM 
imidazole, 0.05% Tween-20, 6 mM sodium ascorbate, pH 8.0). A complete protease 
cocktail inhibitor (Roche, Indianapolis, IN) was also added. Cells were then lysed by 
sonification and centrifuged at 14,000 rpm for 25 minutes at 4 ºC. The supernatant was 
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applied to Ni-NTA agarose resin (Qiagen, Madison, WI) for two hours at 4 ºC allowing 
6XHis tagged GFP to be bound. The resin was then washed with wash buffer (50 mM 
NaH2PO4, 300 mM NaCl, 30 mM imidazole, 10 mM sodium ascorbate, pH 8.0). L-
DOPA incorporated GFP was then eluted from the beads with elution buffer (50 mM 
NaH2PO4, 300 mM NaCl, 500 mM imidazole, pH 8.0). A Nanocep 10K Omega 
centrifugal device (Pall Corp., Port Washington, NY) was used to concentrate the eluted 
protein. Concentrated protein was resolved by SDS-PAGE using a 14% Tris-glycine 
polyacrylamide gel (Invitrogen, Calsbad, CA) in SDS running buffer (25 mM Tris base, 
192 mM glycine, 0.1% SDS, pH 8.3). Proteins were then transferred onto an Immobilon 
PVDF membrane (Millipore) in transfer buffer (48 mM Tris base, 39 mM glycine, 20% 
methanol (v/v), pH 9.2) using a BioRad Semi-Dry Blotter. The membrane was then 
probed for full length GFP expression using a monoclonal anti-EGFP antibody (Clontech, 
Mountain View, CA) and a goat anti-mouse polyclonal antibody conjugated with 
horseradish perodixase (Bio-Rad, Hercules, CA). To visualize the bands, ECL Western 
Blotting Detection Reagents (GE Healthcare, Sweden) was applied to the membrane for 5 
minutes and exposed to a BioMax light film (Eastman Kodak Co., Rochester, NJ). 
Staining of L-DOPA incorporated GFP was carried by first rinsing the membrane with 
deionized water after transferring and stained in staining solution (2 M sodium glycinate, 






4.2 WORKING TOWARDS THE INCORPORATION OF OTHER NONNATURAL AMINO ACIDS IN 
MAMMALIAN CELLS 
4.2.1 Introduction 
The advantage of using the connective polypeptide 1 (CP1) transplantation 
approach to develop orthogonal pairs for incorporation is that it allows us to rapidly 
shuttle previously evolved nonnatural aaRS into mammalian systems. Several nonnatural 
aaRS have been evolved from M. jannaschii TyrRS. These mutant enzymes, when paired 
with an orthogonal suppressor tRNA have been able to incorporate a wide variety of 
nonnatural amino acids in proteins in E. coli cells with specificities > 99% and 
efficiencies up to 75% of wild type (tyrosine) incorporation [5]. Because both the M. 
jannaschii derived tRNA and mutant TyrRS cross-react with eukaryotic tyrosyl-tRNA 
and TyrRS, these pairs have not been used in mammalian systems.  
It is very difficult create a nonnatural aaRS using rationale design. Instead, 
mutants are screened from large genetic libraries (109 variations) using alternating rounds 
of positive and negative selection [6]. The only mammalian cells useable nonnatural 
aaRS have been created by evolving an E. coli TyrRS in yeast cells [7]. These evolved 
aaRS can be used in mammalian cells. However, yeast genetic libraries are smaller in size 
and more difficult to screen than prokaryotic ones. Our approach would allow the 
existing mutant M. jannaschii TyrRS, evolved in E. coli, to be used in mammalian cells. 
The previous section focused on our efforts to incorporate 3,4-dihydroxy-L-
phenylalanine (L-DOPA) using a previously evolved L-DOPA_RS derived from M. 
jannaschii TyrRS. Our final efforts will concentrate on manipulating a couple of other M. 
jannaschii TyrRS evolved nonnatural aaRS. This section will focus on our efforts to 
shuttle the previously evolved pair for p-iodo-L-phenylalanine and p-acetyl-L-




Figure 4.4: The natural amino acid tyrosine and two nonnatural analogs. In order for a 
mutant aaRS to recognize the nonnatural amino acids, its active site must be 
mutated to accommodate the difference in side chain structure. Both ketone 
and iodo functional groups are not found on any of the twenty natural amino 
acids. Both have been successful incorporated into mammalian cells using 
an E. coli derived pair [8] and into prokaryotic cells using a M. jannaschii 
derived pair [9, 10].  
 
4.2.2 Results and Discussion 
Xie et al. previously evolved a nonnatural aaRS with specificity for p-iodo-L-
phenylalanine (p-iodo). This mutant M. jannaschii TyrRS contained five mutations in its 
active site that are responsible for recognizing the amino acid (Leu32, Ser107, Pro158, 
Leu159 and Glu162) [10]. As discussed before, their M. jannaschii derived pair is not 
orthogonal in mammalian cells. Since a CP1 substitution was able to change the 
orthogonality (tRNA specificity) of M. jannaschii TyrRS we season that a similar 
approach could be done to the P-IODO specific aaRS. The E. coli TyrRS’s CP1 domain 
was substituted into the P-IODO aaRS to make P-IODO_39CP1. We hope this would 
change its tRNA specificity from recognizing a C1:G72 sequence to a G1:C72. As a 
result, it would no longer recognize endogenous tyrosyl-tRNA’s but can charge a 1bp-
tRNACUA, completing an orthogonal pair.  
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 We tested the incorporation efficiency of this pair by using a functional assay 
(previously described). A GFP gene harboring an amber stop codon, GFP_40TAG, was 
transfected into HEK293T cells along with H1_1bp-tRNACUA and P-IODO_39CP1. 24 
hours later P-IODO was added to the growth medium. 96 hours after transfection the 




Figure 4.5: Measuring the amount of fluorescent cells using FACS. The P-IODO_39CP1 
was able to charge 1bp-tRNACUA in the absence of P-IODO. Most likely, 
it was still able to recognize tyrosine. Addition of P-IODO caused a <1.5% 
increase in fluorescing cells. This suggests that P-IODO_39CP1 was able to 
recognize P-IODO and charge it to 1bp-tRNACUA. 
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As in the case of L-DOPA incorporation, when all three plasmids were present 
but P-IODO not supplied we still saw some increase in full length GFP expression. This 
is most likely due to charging of 1bp-tRNACUA with a natural amino acid such as 
tyrosine. However, when P-IODO was added we saw a 2% increases in suppression 
efficiency. This could be due to a P-IODO charged 1bp-tRNACUA. 
We also applied our CP1 methodology to a previously evolved nonnatural aaRS 
with specificity for p-acetyl-L-phenylalanine (P-KETO). The P-KETO specific aaRS was 
also evolved from M. jannaschii TyrRS and contains the following mutations in its active 
site: Leu32, Gly158, Cys159, and Arg162 [9]. Other groups have shown that this P-
KETO aaRS has very high fidelity (>99.8%) and activity. It is able to yield of more than 
>3.6 mg of incorporated protein per 1 L of E. coli culture. We applied our CP1 
transplantation to the P-KETO aaRS to make P-KETO_39CP1. The pair was tested using 
a similar assay that was used to test P-IODO (Figure 4.6). It seems that the P-
KETO_39CP1, just like P-IODO_39CP1 and L-DOPA_39CP1, is able to still recognize 
natural amino acids in the absence of the nonnatural amino acid. Addition of P-KETO 
caused a very small increase in the population of fluorescing cells. As in the case with the 
P-IODO results, FACS cannot tell us the identity of the incorporated amino acid so 





Figure 4.6: Measuring the amount of fluorescent cells using FACS. The P-
KETO_39CP1 was able to charge 1bp-tRNACUA in the absence of the 
nonnatural amino acid. Adding P-KETO resulted in a <1% increase in 
fluorescing cells, possible due to incorporation of P-KETO.  
 This section demonstrated our application of the CP1 substitution on two different 
nonnatural aaRS. In both cases, we observed a suspected drop in amino acid fidelity. The 
CP1 substitution might be allowing it to recognize some natural amino acids such as 
tyrosine. However, when the nonnatural amino acid was present, we did see more 
charged 1bp-tRNACUA. Subsequent experiments will have to be conducted to verify the 
identity of the amino acid on 1bp-tRNACUA. Other nonnatural aaRS can also be CP1 




4.2.3 Materials and Methods 
Cell Culturing and Transfection of HEK293T Cells 
 Plasmids were amplified by transforming electrically component E. coli TOP10 
cells, grown in LB, and isolated using QIAprep Spin Miniprep Kit (Qiagen, Madison, 
WI). HEK293T cells (ATCC CRL-11268) were cultured in Dulbecco’s Modified Eagle 
Medium (D-MEM) supplemented with 10% (v/v) fetal bovine serum (Atlanta 
Biologicals, #C0136) at 37 ºC in a humidified incubator containing 5% CO2. 
Transfections complexes were formed using FuGENE HD (Roche, Indianapolis, IN). 
Plasmids were diluted in OPTI-MEM (Invitrogen, Carlsbad, CA) and FuGENE HD was 
added at a 2:1 (µL FuGENE HD: µg DNA). After 15 minutes, this was added to 
HEK293T cells (confluency 40-60%) in T-75 culture flasks. 
 
Plasmid Construction 
 The construction of the GFP_40TAG and H1-1bp-tRNACUA plasmids is described 
in previous chapters. P-KETO_39CP1 was generated by replacing amino acid 110-148 in 
the P-KETO specific aaRS with amino acids 129-167 from E. coli TyrRS. The 5’ 
segment (segment 1) of a previously evolved P-KETO aaRS gene was amplified from the 
plasmid containing the mutant gene (Gift from Dr. Peter G. Schultz, The Scripps 
Research Institute, La Jolla, CA) with the following primers: 
5’-GCGGATCCGCCACCATGGACGAATTTGAAATGATAAAGAGAA‘3 
5’-ACATTCATATTGCCGAACCAATAAACATATTTTGCCTT-‘3 









The segment 1 forward and segment 2 reverse primers were used to amplify a sequence 
containing segments 1 and 2. Finally, this segment 1_2 joined to segment 3 by PCR using 
segment 1 forward and segment 3 reverse primers. This gene also contained a Kozak 
initiation sequence and the Arg286 mutation. The segment 1_2_3 PCR product was 
digested with BamHI and XbaI (New England Biolabs, Ipswich, MA) and ligated using 
DNA T4 Ligase into a predigested pEF6-V5 (Invitrogen, Carlsbad, CA) to create P-
KETO_39CP1. P-IODO_39CP1 was generated in a similar manner, using the same 
primers. A P-IODO aaRS, evolved from M. jannaschii TyrRS, was used as a template 
(Gift from Dr. Peter G. Schultz, The Scripps Research Institute, La Jolla, CA).  
 
Genetic Incorporation of P-IODO and P-KETO 
 HEK293T cells were transfected in six-well plates (2 mL media each). 24 hours 
later, the media was supplement with the nonnatural amino acid at 5 mM. After 72 hours, 
the cells were harvested, fixed in PBS containing 4% paraformaldehyde in (USB Corp., 
Cleveland, OH) and stored at 4 ºC for FACS analysis. Both P-KETO (Chem-Impex, 
Dale, IL) and P-IODO (Fischer Scientific, Pittsburgh, PA) were purchased commercially.   
 
FACS Analysis 
  A BD FACSCalibur flow cytometer was used to gate approximately 10,000 cells 
based on forward and side scatter. Each cell was then excited with 488 nm light and its 
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resulting emission detected with an FL-1 filter (515-545 nm). Positive fluorescent 
populations were gated based on negative controls or positive controls and analyzed 
using the computer software Cyflogic v.1.2.1 (CyFlo, Ltd., Turku, Finland). 
 
4.3 CONCLUSION 
 The development of orthogonal nonnatural suppressor tRNA/aaRS pairs is a 
challenging and tedious process. Our objective was to outline an approach that can be 
used to rapidly create nonnatural tRNA/aaRS pairs for use in mammalian systems. 
Dozens of these pairs have already been evolved from M. jannaschii tyrosyl-
tRNA/TyrRS and can be used use in prokaryotic systems. Our approach involves the 
manipulation of the orthogonality of these pairs to make them applicable. We did this in a 
three step approach. Chapter 2 discussed our efforts to switch the orthogonality of a M. 
jannaschii tyrosyl-tRNA derived suppressor tRNA. Our efforts resulted in the proficient 
expression of a functional and orthogonal amber codon suppressing tRNA (1bp-
tRNACUA). Chapter 3 centered on the manipulation of the corresponding M. jannaschii 
TyrRS. A CP1 substitution was used to change the TyrRS’s recognition of a C1:G72 
containing tRNA to a G1:C72. As a result, it should be orthogonal in mammalian cells 
since it could no longer recognize endogenous tyrosyl-tRNAs that contain a C1:G72. 
Furthermore, the CP1 substitution gave it the ability it to recognize and charge our 
G1:C72 containing tRNA.  
 In this final chapter, we completed our nonnatural tRNA/aaRS pair by applying 
the CP1 substitution to some mutant M. jannaschii TyrRS. Three previously evolved 
nonnatural aaRS were manipulated with the CP1 substitution and tested for their ability 
to charge 1bp-tRNACUA with their respective nonnatural amino acid. We then combined 
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the nonnatural CP1 swapped aaRS with our orthogonal suppressor tRNA to form an 
orthogonal pair. We investigated the ability of these three pairs to site-specifically 
incorporate a nonnatural amino acid in response to an amber stop codon in a gene. Efforts 
to incorporate 3,4-dihydroxy-L-phenylalanine (L-DOPA) yielded promising results but 
will require optimization. The incorporation of P-IODO and P-KETO might have been 
successful but is yet unconfirmed. Our low incorporation efficiency in mammalian cells 
is lower than the observed incorporation in prokaryotic cells (using a NON-CP1 swapped 
M. jannaschii pair). It is almost certain that mutating the aaRS’s specificity for both its 
amino acid and tRNA will negatively impact its activity. Depending on the already 
existing active site mutations, the additional CP1 substitution may be too much of a 
change to maintain the specificity and functionality of the synthetase. However, we 
believe that our approach can be tested with other nonnatural aaRS that were also evolved 
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Figure A.1: CP1 substitutions for the various TyrRS mutations. Column 2 shows the 
amino acids removed from M. jannaschii TyrRS and replaced with amino 
















Figure A.2: FACS analysis using CyFlogic of acceptor stem modifications. Well A: 
GFP_40TAG, Well B: GFP_40TAG and H1-wt-tRNACUA, Well C: 
GFP_40TAG and H1-1bp-tRNACUA, Well D: GFP_40TAG and H1-2bp-













Figure A.3: FACS analysis using Cyflogic of E. Coli TyrRS charging 1bp-tRNACUA. 
Tube 7: GFP_40TAG, Tube 8: GFP_40TAG, H1_wt-tRNACUA, Tube 9: 
GFP_40TAG, H1_1bp-tRNACUA, Tube 10: GFP_40TAG, H1_wt-tRNACUA, 
E. coli TyrRS 
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Figure A.4: FACS analysis using Cyflogic of TyrRS_44CP1 charging 1bp-tRNACUA. 














Figure A.5: FACS analysis using Cyflogic of TyrRS_44CP1_R charging 1bp-tRNACUA. 
Left: GFP_40TAG, Middle: GFP_40TAG, 6x_1bp-tRNACUA, Right: 












Figure A.6: FACS analysis using Cyflogic of TyrRS_44CP1_R charging 1bp-tRNACUA. 
Left: GFP, Left-Middle: GFP_40TAG, Right-Middle: GFP_40TAG  











Figure A.7: FACS analysis using Cyflogic of TyrRS_39CP1_2 charging 1bp-tRNACUA. 
Left: GFP_40TAG, Left-Middle: GFP_40TAG, H1_wt-tRNACUA Right-













Figure A.8: FACS analysis using Cyflogic of TyrRS_36CP1 charging 1bp-tRNACUA. 














Figure A.9: FACS analysis using Cyflogic of RED CP1 substituted mutants charging 
1bp-tRNACUA. Left: GFP_40TAG, H1_1bp-tRNACUA, Left-Middle: 
GFP_40TAG, H1_1bp-tRNACUA, TyrRS_29RED, Right-Middle: 











Figure A.10: FACS analysis using Cyflogic of T. thermophilus CP1 substituted mutants 
charging 1bp-tRNACUA. Left: GFP_40TAG, H1_1bp-tRNACUA, Middle: 









Figure A.11: FACS analysis using Cyflogic of TyrRS_fullCP1 charging 1bp-tRNACUA. 











Figure A.12: FACS analysis using Cyflogic of M. jannaschii TyrRS charging 1bp-
tRNACUA. Left: GFP_40TAG, H1_1bp-tRNACUA, Right: GFP_40TAG, 
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